Crown ElectroKinetics (CRKN) 10-Q 24 Aug 23 2023 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2023	Aug. 22, 2023
Document Information Line Items
Entity Registrant Name	Crown Electrokinetics Corp.
Trading Symbol	CRKN
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		3,018,533
Amendment Flag	false
Entity Central Index Key	0001761696
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	333-232426
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-5423944
Entity Address, Address Line One	1110 NE Circle Blvd
Entity Address, City or Town	Corvallis
Entity Address, State or Province	OR
Entity Address, Postal Zip Code	97330
City Area Code	213
Local Phone Number	660.4250
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, $0.0001 par value
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash	$ 36	$ 821
Prepaid and other current assets	756	590
Total current assets	792	1,411
Property and equipment, net	2,366	1,409
Intangible assets, net	1,688	1,598
Right of use asset	797	1,842
Goodwill	652
Deferred debt issuance costs	5,819	150
Other assets	33	180
TOTAL ASSETS	12,147	6,590
Current liabilities:
Accounts payable	1,822	865
Accrued expenses	408	621
Lease liability - current portion	484	574
Warrant liability	2,721	972
Notes payable at fair value	1,470	1,654
Notes payable	330	8
Total current liabilities	7,235	4,694
Lease liability - non-current portion	355	1,366
Total liabilities	7,590	6,060
Commitments and Contingencies (Note 14)
STOCKHOLDERS’ EQUITY:
Preferred stock, par value $0.0001; 50,000,000 shares authorized, no shares outstanding
Series A preferred stock, par value $0.0001; 300 shares authorized, 251 shares outstanding as of June 30, 2023 and December 31, 2022; liquidation preference $260 as of June 30, 2023 and December 31, 2022
Series B preferred stock, par value $0.0001; 1,500 shares authorized, 1,443 shares outstanding as of June 30, 2023 and December 31, 2022; liquidation preference $1,492 as of June 30, 2023 and December 31, 2022
Series C preferred stock, par value $0.0001; 600,000 shares authorized, 500,756 shares outstanding as of June 30, 2023 and December 31, 2022; liquidation preference $511 as of June 30, 2023 and December 31, 2022
Series D preferred stock, par value $0.0001; 7,000 shares authorized, 0 shares issued and outstanding as of June 30, 2023 and 1,058 as of December 31, 2022; liquidation preference 0 as of June 30, 2023 and $1,113 as of December 31, 2022
Series E preferred stock, par value $0.0001; 77,000 shares authorized, 21,000 shares committed pending shareholder approval as of June 30, 2023 and no shares outstanding as of December 31, 2022
Series F preferred stock, par value $0.0001; 9,073 shares authorized, 5,251 shares outstanding as of June 30, 2023 and no shares outstanding as of December 31, 2022
Series F-1 preferred stock, par value $0.0001; 9,052 shares authorized, 3,583 shares outstanding as of June 30, 2023 and no shares outstanding as of December 31, 2022.
Series F-2 preferred stock, par value $0.0001; 9,052 shares authorized, 1,153 shares outstanding as of June 30, 2023 and no shares outstanding as of December 31, 2022.
Common stock, par value $0.0001; 800,000,000 shares authorized; 1,067,341 and 337,392 shares outstanding as of June 30, 2023 and December 31, 2022, respectively	6	2
Additional paid-in capital	109,381	88,533
Accumulated deficit	(104,830)	(88,005)
Total stockholders’ equity	4,557	530
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 12,147	$ 6,590

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	800,000,000	800,000,000
Common stock, shares outstanding	1,067,341	337,392
Series A Preferred Stock
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	300	300
Preferred stock, shares outstanding	251	251
Liquidation preference (in Dollars)	$ 260	$ 0
Preferred stock, shares issued	251	251
Series B Preferred Stock
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,500	1,500
Preferred stock, shares outstanding	1,443	1,443
Liquidation preference (in Dollars)	$ 1,492	$ 0
Preferred stock, shares issued	1,443	1,443
Series C Preferred Stock
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	600,000	600,000
Preferred stock, shares outstanding	500,756	500,756
Liquidation preference (in Dollars)	$ 511	$ 0
Preferred stock, shares issued	500,756	500,756
Series D Preferred Stock
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	7,000	7,000
Preferred stock, shares outstanding	0	1,058
Liquidation preference (in Dollars)	$ 0	$ 1,113
Preferred stock, shares issued	0	1,058
Series E Preferred Stock
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	77,000	77,000
Preferred stock, shares outstanding	21,000
Series F preferred stock
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	9,073	9,073
Preferred stock, shares outstanding	5,251
Series F-1 Preferred Stock
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	9,052	9,052
Preferred stock, shares outstanding	3,583
Series F-2 Preferred Stock
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	9,052	9,052
Preferred stock, shares outstanding	1,153

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenue	$ 37		$ 59
Cost of revenue	23		54
Gross profit	14		5
Operating expenses:
Research and development	490	1,473	1,031	2,568
Selling, general and administrative	4,409	3,002	7,985	6,474
Total operating expenses	4,899	4,475	9,016	9,042
Loss from operations	(4,885)	(4,475)	(9,011)	(9,042)
Other income (expense):
Interest expense	(2,508)	(2)	(4,525)	(5)
Loss on extinguishment of warrant liability			(504)
Loss on extinguishment of debt	(2,345)		(2,345)
Gain on issuance of convertible notes			64
Change in fair value of warrants	2,130		7,736
Change in fair value of notes	(6,883)		(7,000)
Other expense	(28)		(1,234)
Total other income (expense)	(9,634)	(2)	(7,808)	(5)
Loss before income taxes	(14,519)	(4,477)	(16,819)	(9,047)
Income tax expense
Net loss	(14,519)	(4,477)	(16,819)	(9,047)
Deemed dividend on Series D preferred stock			(6)
Net loss attributable to common stockholders	$ (14,616)	$ (4,477)	$ (16,997)	$ (9,047)
Net loss per share attributable to common stockholders (in Dollars per share)	$ (18.02)	$ (16.35)	$ (25.96)	$ (33.62)
Weighted average shares outstanding, basic (in Shares)	810,983	273,767	653,848	269,094
Series A Preferred Stock
Other income (expense):
Cumulative dividends	$ (5)		$ (9)
Series B Preferred Stock
Other income (expense):
Cumulative dividends	(29)		(49)
Series C Preferred Stock
Other income (expense):
Cumulative dividends	(10)		(10)
Series D Preferred Stock
Other income (expense):
Cumulative dividends	$ (53)		$ (84)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Weighted average shares outstanding, diluted	810,983	273,767	653,848	269,094

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) - USD ($) $ in Thousands	Series A Preferred Stock	Series B Preferred Stock	Series C Preferred Stock	Series D Preferred Stock	Series E Preferred Stock	Series F Preferred Stock	Common Stock Common Stock	Series F-1 Preferred Stock Preferred Stock	Series F-2 Preferred Stock Preferred Stock	Series F-1 Preferred Stock	Series F-2 Preferred Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2021							$ 1					$ 82,677	$ (73,690)	$ 8,988
Balance (in Shares) at Dec. 31, 2021	251	1,443	500,756				242,808
Balance at Jun. 30, 2022							$ 1					85,489	(82,737)	2,753
Balance (in Shares) at Jun. 30, 2022	251	1,443	500,756				244,217
Exercise of common stock warrants												223		223
Issuance of common stock/At-the-market offering, net of offering costs												58		58
Issuance of common stock/At-the-market offering, net of offering costs (in Shares)							853
Delivery of restricted common stock (in Shares)							556
Stock-based compensation												2,531		2,531
Net loss													(9,047)	(9,047)
Balance at Mar. 31, 2022							$ 1					83,983	(78,260)	5,724
Balance (in Shares) at Mar. 31, 2022	251	1,443	500,756				243,364
Balance at Jun. 30, 2022							$ 1					85,489	(82,737)	2,753
Balance (in Shares) at Jun. 30, 2022	251	1,443	500,756				244,217
Issuance of common stock/At-the-market offering, net of offering costs												58		58
Issuance of common stock/At-the-market offering, net of offering costs (in Shares)							853
Issuance of Series D preferred stock and warrants, net of fees												464		464
Issuance of Series D preferred stock and warrants, net of fees (in Shares)									1,153
Stock-based compensation												1,448		1,448
Net loss													(4,477)	(4,477)
Balance at Dec. 31, 2022							$ 2					88,533	(88,005)	530
Balance (in Shares) at Dec. 31, 2022	251	1,443	500,756	1,058			338,033
Balance at Jun. 30, 2023							$ 6					109,381	(104,830)	4,557
Balance (in Shares) at Jun. 30, 2023	251	1,443	500,756			5,251	1,067,997	3,583	1,153	3,583	1,153
Exercise of common stock warrants							$ 1					2,061		2,062
Exercise of common stock warrants (in Shares)							109,257
Issuance of common stock in connection with conversion of notes												516		516
Issuance of common stock in connection with conversion of notes (in Shares)							31,466
Issuance of common stock/At-the-market offering, net of offering costs							$ 1					2,106		2,107
Issuance of common stock/At-the-market offering, net of offering costs (in Shares)							211,667
Issuance of Series E preferred stock in connection with LOC												4,350		4,350
Issuance of Series E preferred stock in connection with LOC (in Shares)					5,000
Deemed dividend for repricing of Series D preferred stock												6	(6)
Commitment to issue shares of common stock in connection with March waiver agreement												298		298
Issuance of common stock in connection with Series A and Series B Dividends
Issuance of common stock in connection with Series A and Series B Dividends (in Shares)							6,921
Issuance of common stock upon the conversion of Series E preferred stock							$ 1							1
Issuance of common stock upon the conversion of Series E preferred stock (in Shares)					(5,000)		83,334
Issuance of common stock in connection with conversion of October Notes							$ 1					2,165		2,166
Issuance of common stock in connection with conversion of October Notes (in Shares)							248,984
Dividends paid in shares of Series D preferred stock
Dividends paid in shares of Series D preferred stock (in Shares)				139
Series D preferred stock exchanged for Series F preferred stock in connection with Exchange Agreements												(450)		(450)
Series D preferred stock exchanged for Series F preferred stock in connection with Exchange Agreements (in Shares)				(1,197)		1,847
Conversion of Demand Notes and October Notes into Series F preferred stock in connection with Exchange Agreements												1,276		1,276
Conversion of Demand Notes and October Notes into Series F preferred stock in connection with Exchange Agreements (in Shares)						3,198
Conversion of January Notes into Series F preferred stock in connection with Exchange Agreements												82		82
Conversion of January Notes into Series F preferred stock in connection with Exchange Agreements (in Shares)						206
Issuance of Series F-1 preferred stock												1,372		1,372
Issuance of Series F-1 preferred stock (in Shares)										3,583
Issuance of Series F-2 preferred stock												464		464
Issuance of Series F-2 preferred stock (in Shares)											1,153
Commitment to issue shares of common stock in connection with January Notes												2,410		2,410
Commitment to issue shares of common stock in connection with LOC Notes												230		230
Commitment to issue shares of Series E preferred stock in connection with LOC Notes												3,363		3,363
Commitment to issue shares of common stock in connection with Demand Notes												286		286
Stock-based compensation												313		313
Stock-based compensation (in Shares)							38,335
Net loss													(16,819)	(16,819)
Balance at Mar. 31, 2023							$ 4					98,051	(90,311)	7,744
Balance (in Shares) at Mar. 31, 2023	251	1,443	500,756	1,058	5,000		728,758
Balance at Jun. 30, 2023							$ 6					109,381	(104,830)	4,557
Balance (in Shares) at Jun. 30, 2023	251	1,443	500,756			5,251	1,067,997	3,583	1,153	3,583	1,153
Issuance of common stock in connection with Series A and Series B Dividends
Issuance of common stock in connection with Series A and Series B Dividends (in Shares)							6,921
Issuance of common stock upon the conversion of Series E preferred stock							$ 1							1
Issuance of common stock upon the conversion of Series E preferred stock (in Shares)					(5,000)		83,334
Issuance of common stock in connection with conversion of October Notes							$ 1					2,165		2,166
Issuance of common stock in connection with conversion of October Notes (in Shares)							248,984
Dividends paid in shares of Series D preferred stock
Dividends paid in shares of Series D preferred stock (in Shares)				139
Series D preferred stock exchanged for Series F preferred stock in connection with Exchange Agreements												(450)		(450)
Series D preferred stock exchanged for Series F preferred stock in connection with Exchange Agreements (in Shares)				(1,197)		1,847
Conversion of Demand Notes and October Notes into Series F preferred stock in connection with Exchange Agreements												1,276		1,276
Conversion of Demand Notes and October Notes into Series F preferred stock in connection with Exchange Agreements (in Shares)						3,198
Conversion of January Notes into Series F preferred stock in connection with Exchange Agreements												82		82
Conversion of January Notes into Series F preferred stock in connection with Exchange Agreements (in Shares)						206
Issuance of Series F-1 preferred stock												1,372		1,372
Issuance of Series F-1 preferred stock (in Shares)								3,583
Commitment to issue shares of common stock in connection with January Notes												2,410		2,410
Commitment to issue shares of common stock in connection with LOC Notes												230		230
Commitment to issue shares of Series E preferred stock in connection with LOC Notes												3,363		3,363
Commitment to issue shares of common stock in connection with Demand Notes												286		286
Stock-based compensation												132		132
Net loss													$ (14,519)	$ (14,519)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (16,819)	$ (9,047)
Stock-based compensation	313	2,531
Depreciation and amortization	372	234
Loss on extinguishment of warrant liability	504
Change in fair value of warrant liability	(7,736)
Loss on extinguishment of debt	2,345
Change in fair value of notes	7,000
Amortization of deferred debt issuance costs	4,049
Amortization of right of use assets	1,045	239
Other expenses	1,275
Loss on disposal of equipment	235	52
Changes in operating assets and liabilities:
Prepaid and other assets	(14)	3
Accounts payable	886	370
Accrued expenses	(742)	(182)
Lease liability	(1,101)	(143)
Net cash used in operating activities	(8,388)	(5,943)
CASH FLOWS FROM INVESTING ACTIVITIES
Cash paid for acquisition of Amerigen 7	(644)
Purchase of equipment	(707)	(258)
Purchase of patents		(61)
Net cash used in investing activities	(1,351)	(319)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from the exercise of warrants	2,061
Proceeds from the issuance of common stock / At-the-market offering	2,198	60
Proceeds from the issuance of notes in connection with Line of Credit	2,350
Offering costs for the issuance of common stock / At-the-market offering	(91)	(2)
Proceeds from a deposit for Series D preferred stock (shares liability)		1,058
Proceeds from issuance of Series F-1 preferred stock	2,328
Proceeds from issuance of Series F-2 preferred stock	748
Proceeds from issuance of January promissory notes, net of fees paid	1,357
Repayment of notes payable	(1,997)
Net cash provided by financing activities	8,954	1,116
Net increase / decrease in cash	(785)	(5,146)
Cash — beginning of period	821	6,130
Cash — end of period	36	984
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Issuance of Series E preferred stock in connection with LOC	9,943
Issuance of Series F preferred stock in connection with exchange of Series D preferred stock	450
Issuance of common stock in connection with conversion of notes	516
Issuance of common stock warrants in connection with SLOC		223
Deemed dividend for repricing of Series D preferred stock	6
Commitment to issue shares of common stock in connection with Demand Notes	286
Unpaid equipment included in accounts payable	92	112
SUPPLEMENTAL CASH FLOW INFORMATION
Cash paid for interest	$ 8	$ 3

Organization and Description of

Organization and Description of Business Operations	6 Months Ended
	Jun. 30, 2023
Organization and Description of Business Operations [Abstract]
Organization and Description of Business Operations	Note 1 - Organization and Description of Business Operations Crown Electrokinetics Corp. (the “Company”) was incorporated in the State of Delaware on April 20, 2015. Effective October 6, 2017, the Company’s name was changed to Crown Electrokinetics Corp. from 3D Nanocolor Corp. (“3D Nanocolor”). On January 26, 2021, the Company completed its public offering, and its common stock began trading on the Nasdaq Capital Market (Nasdaq) under the symbol CRKN. The Company is commercializing technology for smart or dynamic glass. The Company’s electrokinetic glass technology is an advancement on microfluidic technology that was originally developed by HP Inc. On December 20, 2022, the Company incorporated Crown Fiber Optics Corp., a Delaware based entity, to own and operate its acquired business from the acquisition of Amerigen 7, LLC (“Amerigen 7”) in January 2023. Crown Fiber Optics Corp. is accounted for as a wholly- owned subsidiary of Crown Electrokinetics, Corp. Preferred Stock Subsequent to December 31, 2022, the Company filed the first amendment to its Series D preferred stock, which modifies the conversion price of the Series D preferred stock from $78.00 to $30.00 per share (See Note 12). On February 1, 2023, the Company’s Board of Directors authorized 77,000 shares of Series E preferred stock with a par value of $0.0001 per share. Each share of Series E Preferred Stock is convertible into 1,000 shares of the Company’s common stock at the option of the holders (See Note 12). On June 4, 2023, the Company’s Board of Directors authorized 9,073 shares of Series F preferred stock with a par value of $0.0001 per share. Each share of Series F Preferred Stock has a stated value of $1,000 and is convertible at the option of the holders into shares of the Company’s common stock at an initial conversion price of $8.868 (See Note 12). On June 13, 2023, the Company’s Board of Directors authorized 9,052 shares of Series F-1 preferred stock with a par value of $0.0001 per share. Each share of Series F-1 Preferred Stock has a stated value of $1,000 and is convertible at the option of the holders into shares of the Company’s common stock at an initial conversion price of $8.994 (See Note 12). On June 14, 2023, the Company’s Board of Directors authorized 9,052 shares of Series F-2 preferred stock with a par value of $0.0001 per share. Each share of Series F-2 Preferred Stock has a stated value of $1,000 and is convertible at the option of the holders into shares of the Company’s common stock at an initial conversion price of $9.228 (See Note 12). Business Combination On January 3, 2023, the Company acquired certain assets related to the construction of 5G fiber optics infrastructure and distributed antenna systems from Amerigen 7 (the “Business Combination”), for cash consideration of approximately $0.65 million (See Note 4). Reverse Stock Split On August 11, 2023, the Company’s Board of Directors authorized a reverse stock split (‘Reverse Stock Split”) at an exchange ratio of one (1) share of common stock for every sixty (60) shares of common stock. The Reverse Stock Split was effective on August 15, 2023, such that every sixty (60) shares of common stock have been automatically converted into one (1) share of common stock. The Company did not issue fractional certificates for post-reverse split shares in connection with the Reverse Stock Split. Rather, all shares of common stock that were held by a stockholder were aggregated and each stockholder was entitled to receive the number of whole shares resulting from the combination of the shares so aggregated. Any fractions resulting from the Reverse Stock Split computation were rounded up to the next whole share. The number of authorized shares of the common stock was not adjusted as a result of the Reverse Stock Split. All share and per share data in these condensed consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented. The shares of common stock retain a par value of $0.0001 per share. Accordingly, an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split was reclassified from common stock to additional paid-in capital.

Liquidity, Financial Condition,

Liquidity, Financial Condition, and Going Concern	6 Months Ended
	Jun. 30, 2023
Liquidity and Financial Condition [Abstract]
Liquidity, Financial Condition, and Going Concern	Note 2 – Liquidity, Financial Condition, and Going Concern The Company has incurred substantial operating losses since its inception and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As reflected in the condensed consolidated financial statements, the Company had an accumulated deficit of approximately $104.8 million and negative working capital of approximately $6.4 million at June 30, 2023, a net loss of approximately $17.0 million, and approximately $8.4 million of net cash used in operating activities for the six months ended June 30, 2023. The Company expects to continue to incur ongoing administrative and other expenses, including public company expenses. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. The Company will seek to obtain additional capital through the sale of debt or equity financings or other arrangements to fund operations including through its existing At-The-Market offering, $10 million Standing Letter of Credit (“SLOC”), the $100 million Line of Credit, and the $50 million Equity Line of Credit (Note 15 Subsequent Event); however, there can be no assurance that the Company will be able to raise needed capital under acceptable terms, if at all. The sale of additional equity may dilute existing stockholders and newly issued shares may contain senior rights and preferences compared to currently outstanding shares of common stock. Issued debt securities may contain covenants and limit the Company’s ability to pay dividends or make other distributions to stockholders. If the Company is unable to obtain such additional financing, future operations would need to be scaled back or discontinued. Due to the uncertainty in the Company’s ability to raise capital, management believes that there is substantial doubt in the Company’s ability to continue as a going concern for twelve months from the issuance of these condensed consolidated financial statements. At-the-Market Offerings The Company entered into a Sales Agreement with A.G.P./Alliance Global Partners (the “Sales Agents”) dated March 30, 2022 (the “Sales Agreement”), pursuant to which the Company may, from time to time, sell up to $5.0 million in shares (the “Placement Shares”) of the Company’s common stock through the Sales Agents, acting as the Company’s sales agent and/or principal, in a continuous at-the-market offering (the “ATM Offering”). The Company will pay the Sales Agents a commission of up to 3.0% of the aggregate gross proceeds the Company receives from all sales of the Company’s common stock under the Sales Agreement. The Placement Shares will be offered and sold pursuant to the Company’s shelf registration statement on Form S-3 (Registration No. 333- 262122) and the related base prospectus included in the registration statement, as supplemented by the prospectus supplement dated March 30, 2022. During the six months ended June 30, 2023, the Company received net proceeds on sales of shares of common stock under the Sales Agreement of approximately $2.1 million (after deducting $0.1 million in commissions and expenses) at a weighted average price of $10.38 per share. On July 5, 2023, the Company and the Sales Agents filed the second amendment to the Sales Agreement (the “Second Amendment to the Sales Agreement”). Pursuant to the First Amendment to the Sales Agreement, the Company may from time to time, sell up to $5.1 million in Placement Shares of the Company’s common stock through the Sales Agents in a continuous At-the-Market Offering (the Amended ATM Offering”). According to the First Amendment to the Sales Agreement, the Company will pay the Sales Agents a commission of up to 3.0% of the aggregate gross proceeds the Company receives from all sales of its common stock in the Amended ATM Offering. Subsequent to June 30, 2023, the Company received net proceeds on sales of 545,100 shares of common stock of approximately $1.59 million (after deducting $0.76 million in commissions and expenses) at a weighted average price of $3.05 per share. Line of Credit On February 2, 2023, the Company entered into a line of credit agreement (the “Line of Credit”) securing a line of credit up to $100.0 million. The Line of Credit will be used to fund expenses related to the fulfillment of contracts with customers of the Company’s wholly-owned subsidiary, Crown Fiber Optics Corporation (See Note 1). The Line of Credit expires February 2, 2024, unless the Line of Credit is extended for one or two additional years in accordance with its terms. On February 2, 2023, the Company drew down $2.0 million under the Line of Credit. Upon drawing down on the Line of Credit, the Company issued a Secured Promissory Note (the “2023 Note”) which is due and payable 60 days from the issuance date (See Note 11). On May 16, 2023, the Company made a second draw of $0.2 million under the Line of Credit. Upon drawing down on the Line of Credit, the Company issued a second Secured Promissory Note (the “2 nd nd nd On May 26, 2023, the Company made a third draw of $0.15 million under the Line of Credit. Upon drawing down on the Line of Credit, the Company issued a third Secured Promissory Note (the “3 rd rd On June 13, 2023, the Company partially redeemed the principal amount of the 2023 Note and fully redeemed the principal amount of the 2 nd rd Demand Notes Between May 17, 2023 and May 18, 2023, the Company issued secured demand promissory notes (the “Demand Notes”) to certain investors (the “Demand Holders”) in an aggregate principal amount equal to $229,877. The Demand Notes are due and payable at any time upon demand by a Demand Holder after the earlier of (i) the consummation of the Company’s first securities offering after the issuance of the Demand Notes and (ii) July 16, 2023. The Demand Notes do not bear interest. In connection with the issuance of the Demand Notes, the Company agreed to issue, pending shareholder approval, to the Demand Holders an aggregate of 76,626 shares of the Company’s common stock. On May 30, 2023, the Company issued secured demand promissory notes (the “2 nd nd nd nd nd nd nd nd Exchange Agreements On June 4, 2023, the Company entered into Exchange Agreements (the “Exchange Agreements”): (i) with the October Investors for the exchange of October Notes in the aggregate principal amount of $2.6 million for 2,622 shares of the Company’s newly created Series F Convertible Preferred Stock (“Series F Preferred Stock”), in the aggregate; (ii) with the January Investors for the exchange of January Notes in the aggregate principal amount of $0.2 million for 206 shares of Series F Preferred Stock, in the aggregate; (iii) with the Demand Noteholders for the exchange of Demand Notes in the principal amount of $0.6 million for 576 shares of Series F Preferred Stock, in the aggregate; and (iv) with the purchasers of the Company’s Series D Preferred Stock for the exchange of 1,197 shares of Series D Preferred Stock for 1,847 shares of Series F Preferred Stock, in the aggregate. In addition, in connection with the Exchange Agreements, the Company issued new five-year warrants to purchase an aggregate of 592,129 shares of Common Stock (the “Exchange Warrants”) to the October Investors, the January Investors, and the purchasers of the Company’s Series D Preferred Stock. The Exchange Warrants are exercisable at an exercise price of $8.868 per share of Common Stock, subject to certain adjustments as set forth in the Exchange Warrants. The holders may exercise the Exchange Warrants on a cashless basis if the shares of our Common Stock underlying the Exchange Warrants are not then registered pursuant to an effective registration statement. The Company concluded that the Exchange Warrants are liability classified. For the October Investors, the total fair value of Series F Preferred Stock and Warrant Liability issued was $1.7 million ($1.1 million for Series F Preferred Stock and $0.6 million for Warrant Liability). For the January Investors, the total fair value of Series F Preferred Stock and Warrant Liability issued was $0.13 million ($0.1 million for Series F Preferred Stock and $0.03 million for the Warrant Liability). For the Demand Note holders, the total fair value of Series F Preferred Stock and Warrant Liability issued was $0.4 million ($0.2 million for Series F Preferred Stock and $0.2 million for the Warrant Liability). For the purchasers of the Company’s Series D Preferred Stock, the Company accounted for the exchange as an extinguishment of the Series D Preferred Stock. The Company recorded the total fair value of Series F Preferred Stock and Warrant Liability of $1.2 million ($0.7 million for Series F Preferred Stock and $0.5 million for the Warrant Liability) and the difference of $0.5 million with the $0.7 million carrying value of the Series D Preferred Stock as a deemed dividend and reduction to additional-paid-in-capital. Series F-1 Preferred Stock Offering On June 13, 2023, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Purchasers”), pursuant to which, at the closing of the transactions contemplated by the Purchase Agreement (the “Closing”) the Purchasers agreed to purchase an aggregate of 3,583 shares of the Company’s newly created Series F-1 Convertible Preferred Stock (“Series F-1 Preferred Stock”) for an aggregate purchase price of approximately $2.3 million . In addition, in connection with the issuance of the Series F-1 Preferred Stock, the Purchasers will receive five-year warrants to purchase an aggregate of 398,377 shares of Common Stock (defined below) (the “Series F-1 Warrants”). The Series F-1 Warrants will be exercisable at an exercise price of $8.994 per share of the Company’s common stock, subject to certain adjustments as set forth in the Warrants. The holders may exercise the Warrants on a cashless basis if the shares of our Common Stock underlying the Warrants are not then registered pursuant to an effective registration statement. The obligations of the Company and the Purchasers to consummate the transactions contemplated by the Purchase Agreement are subject to the satisfaction on or prior to the Closing of customary closing conditions. Series F-2 Preferred Stock Offering On June 14, 2023, the Company entered into a Securities Purchase Agreement (the “F-2 Purchase Agreement”) with certain accredited investors (the “F-2 Purchasers”), pursuant to which, at the closing of the transactions contemplated by the Purchase Agreement (the “F-2 Closing”) the F-2 Purchasers agreed to purchase an aggregate of 1,153 shares of the Company’s newly created Series F-2 Convertible Preferred Stock (“Series F-2 Preferred Stock”) for an aggregate purchase price of approximately $0.7 million. In addition, in connection with the issuance of the Series F-2 Preferred Stock, the F-2 Purchasers will receive five-year warrants to purchase an aggregate of 124,946 shares of Common Stock (defined below) (the “F-2 Warrants”). The F-2 Warrants will be exercisable at an exercise price of $9.228 per share of Common Stock, subject to certain adjustments as set forth in the F-2 Warrants. The holders may exercise the F-2 Warrants on a cashless basis if the shares of our Common Stock underlying the F-2 Warrants are not then registered pursuant to an effective registration statement. The obligations of the Company and the F-2 Purchasers to consummate the transactions contemplated by the F-2 Purchase Agreement are subject to the satisfaction on or prior to the F-2 Closing of customary closing conditions. Risks and Uncertainties The Company is currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflict between Russia and Ukraine. The Company’s financial condition and results of operations may be materially adversely affected by any negative impact on the global economy and capital markets resulting from the conflict in Ukraine or any other geopolitical tensions. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Significant Accounting Policies [Abstract]
Significant Accounting Policies	Note 3 - Significant Accounting Policies Basis of Presentation The Company’s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented. The condensed consolidated results of operations for the six months ended June 30, 2023 are not necessarily indicative of the results for the full year or the results for any future periods. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes for the fiscal year ended December 31, 2022 included in the Company’s Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2023. Use of Estimates The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s condensed consolidated financial statements relate to the valuation of its business combination, senior secured convertible notes and warrants, Series F/F-1/F-2 Preferred Stock, warrants, and equity-based awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected. Significant Accounting Policies For a detailed discussion about the Company’s significant accounting policies, see the Company’s December 31, 2022 financial statements included in its 2022 Annual Report. Revenue Recognition The Company adopted the new revenue standard, ASC 606, on March 31, 2019 using the full retrospective approach. The adoption did not have an effect on 2021 or 2020 revenue recognition or a cumulative effect on opening equity, as the timing and measurement of revenue recognition is materially the same as under ASC 605. The core principle of the new revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle: ● Step 1: Identify the contract with the customer ● Step 2: Identify the performance obligations in the contract ● Step 3: Determine the transaction price ● Step 4: Allocate the transaction price to the performance obligations in the contract ● Step 5: Recognize revenue when the company satisfies a performance obligation For contracts where the period between when the Company transfers a promised good or service to the customer and when the customer pays is one year or less, the Company has elected the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing component. The Company’s performance obligation is to provide fiber splicing services as required based on short-term work orders as work is assigned by the Customer. The Company is required to complete the description of work described in the work order and test the service provided prior to any recognition of revenue and invoicing. The short-term work orders are for very specific performance obligations which are performed from start to finish within two weeks or less, and more often, within one week. The Company is required to adhere to the rules and regulations that are outlined in the Agreement between the Company and the Customer. Cost for the work performed is outlined in the individual work orders based on the detailed description of work to be performed. All of the revenue is recognized immediately upon completion of the work in each work order. A 5% retainage will be withheld by the Customer upon payment of invoices and will be paid to the Company within one year after termination of the contract. The retainage can be utilized by Customer for any claims that may arise after work is completed up through one year after completion. Revenue recognized during the six months ended June 30, 2023 was generated by the Company’s wholly-owned subsidiary, Crown Fiber Optics Corporation, and was immaterial. No revenue was recognized by the Company during the six months ended June 30, 2022. Financial Instruments – Credit Losses Measurements of Credit Losses on Financial Instruments (“ASC 326”), which replaces the existing incurred loss model with a current expected credit loss (“CECL”) model that requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company would be required to use a forward-looking CECL model for accounts receivables, guarantees and other financial instruments. The Company adopted ASC 326 on January 1, 2023 and ASC 326 did not have a material impact on its financial statements. Segment and Reporting Unit Information Operating segments are defined as components of an entity for which discrete financial information is available that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s Chief Executive Officer is determined to be the CODM. On January 3, 2023, the Company acquired Crown Fiber Optics, Corp. (see Note 1) and is currently in the process of integrating this new business line including identifying leadership, and aligning management reporting and allocation methodologies. The Company is assessing its current segment structure in conjunction with the integration efforts. Business Combinations The Company accounts for business combinations using the guidance provided by Accounting Standards Codification (“ASC”) 805, Business Combinations Accounting for business combinations requires management to make significant estimates and assumptions, especially at the acquisition date, including estimates for intangible assets. Although the Company believes the assumptions and estimates made have been reasonable and appropriate, they are based in part on historical experience and information obtained from management of the acquired companies and are inherently uncertain. Critical estimates in valuing certain intangible assets we have acquired include future expected cash flows from customer contracts. Unanticipated events and circumstances may occur that may affect the accuracy or validity of such assumptions, estimates, or actual results. The initial purchase price may be adjusted as needed per the terms of the arrangement agreement. The allocation of purchase price, including any fair value the assets acquired and liabilities assumed as of the acquisition date has not been completed. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred. Deferred Debt Issuance Costs The Company accounts for debt issuance costs related to its Line of Credit as a deferred asset which is amortized over the life of the Line of Credit. Since the Company has elected the fair value option for its convertible notes (see below), upon a draw down, a portion of the deferred asset balance will be amortized to other expense. On the issuance date of the Company’s Line of Credit, the cost related to issuance of the Series E preferred shares and the warrant to purchase Series E preferred shares was recorded as a deferred asset. Goodwill The Company performs a goodwill impairment analysis on October 1 st Convertible Notes and Notes Payable In accordance with Accounting Standards Codification 825, Financial Instruments Warrants The Company accounted for certain common stock warrants outstanding as a liability at fair value and adjusted the instruments to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s statements of operations. The fair value of the warrants issued by the Company have been estimated using the Black Scholes Methodology. SLOC The Company accounts for its warrants related to the SLOC in accordance with ASC 815-40, Contracts in Entity’s Own Equity. Under the guidance of ASU 2015-15, Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements Purchase Order Warrants The Company accounts for its warrants issued in connection with purchase orders in accordance with ASC 606, Revenue Recognition. Compensation - Stock Compensation (“ ”) Net Loss per Share ASC 260, Earnings Per Share Basic net loss per share of common stock excludes dilution and is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share of common stock reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity unless inclusion of such shares would be anti-dilutive. Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share at June 30, 2023 and 2022 are as follows: June 30, 2023 2022 Series A preferred stock 3,146 3,146 Series B preferred stock 33,883 33,883 Series C preferred stock 9,346 9,346 Series F preferred stock 592,130 - Series F-1 preferred stock 398,377 - Series F-2 preferred stock 124,946 - Convertible notes 11,667 - Warrants to purchase common stock (excluding penny warrants) 1,760,095 78,787 Warrants to purchase Series E preferred stock 750,000 - Options to purchase common stock 157,779 151,892 Unvested restricted stock units 7,139 8,613 Commitment shares 783,806 - 4,632,314 285,667 Emerging Growth Company The Company is considered to be an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended (JOBS Act). The JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has elected to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Securities and Exchange Act of 1934.

Acquisitions

Acquisitions	6 Months Ended
	Jun. 30, 2023
Acquisitions [Abstract]
Acquisitions	Note 4 – Acquisitions On January 3, 2023, the Company completed its Business Combination as described in Note 1. In accordance with the terms of the Business Combination, the Company paid cash consideration of approximately $0.65 million. The Business Combination included approximately 12 employees, customer contracts, and certain operating liabilities. The initial purchase price may be adjusted as needed per the terms of the agreement. The measurement period for the Business Combination will be up to one year from the acquisition date. The following table summarizes the allocation of the purchase price to the assets acquired and liabilities assumed for the Amerigen 7 acquisition (in thousands): Property and equipment $ 655 Intangible assets 200 Security deposits 5 Accrued expenses (529 ) Notes payable (338 ) Total identifiable assets and liabilities acquired (7 ) Goodwill 652 Total purchase consideration $ 645 The Company engaged an independent valuation specialist to conduct a valuation analysis of the identifiable intangible assets acquired by the Company with the objective of estimating the fair value of such assets as of January 3, 2023. The valuation specialist utilized the Income Approach, specifically the Multi-Period Excess Earnings Method, to value the existing customer relationship.

Prepaid and Other Current Asset

Prepaid and Other Current Assets	6 Months Ended
	Jun. 30, 2023
Prepaid and Other Current Assets [Abstract]
Prepaid and Other Current Assets	Note 5 - Prepaid and Other Current Assets Prepaid and other current assets consist of the following (in thousands): June 30, December 31, License fees $ 215 $ 300 Notes receivable - - Professional fees 385 - Insurance 34 142 Hudson warrant * 86 85 Other 36 63 Total $ 756 $ 590 * Fair value of warrant issued to Hudson Pacific Properties, L.P. (See Note 13)

Property & Equipment, Net

Property & Equipment, Net	6 Months Ended
	Jun. 30, 2023
Property & Equipment, Net [Abstract]
Property & Equipment, Net	Note 6 - Property & Equipment, Net Property and equipment, net, consists of the following (in thousands): June 30, December 31, 2023 2022 Equipment $ 2,456 $ 1,457 Leasehold improvements 362 362 Vehicles 159 - Computers 55 52 Other 44 - Total 3,076 1,871 Less accumulated depreciation and amortization (710 ) (462 ) Property and equipment, net $ 2,366 $ 1,409 Depreciation expense for the three months ended June 30, 2023 and 2022 was $0.1 million and $0.1 million, respectively. Depreciation expense for the six months ended June 30, 2023 and 2022 was $0.3 million and $0.1 million, respectively.

Intangible Assets, Net

Intangible Assets, Net	6 Months Ended
	Jun. 30, 2023
Intangible Assets, Net [Abstract]
Intangible Assets, Net	Note 7 - Intangible Assets, Net Intangible assets, net, consists of the following (in thousands): June 30, December 31, 2023 2022 Patents $ 1,800 $ 1,800 Research license 375 375 Customer relationships 200 - Total 2,375 2,175 Accumulated amortization (687 ) (577 ) Intangible assets, net $ 1,688 $ 1,598 The following table represents the total estimated amortization of intangible assets for the five succeeding years and thereafter as of June 30, 2023 (in thousands): Estimated Six months ended December 31, 2023 $ 121 Year ended December 31, 2024 235 Year ended December 31, 2025 234 Year ended December 31, 2026 197 Year ended December 31, 2027 and thereafter 901 Total $ 1,688 For the three months ended June 30, 2023 and 2022, amortization expense was approximately $0.1 million and $0.1 million, respectively. For the six months ended June 30, 2023 and 2022, amortization expense was approximately $0.1 million and $0.1 million, respectively.

Deferred Debt Issuance Costs

Deferred Debt Issuance Costs	6 Months Ended
	Jun. 30, 2023
Deferred Debt Issuance Costs [Abstract]
Deferred Debt Issuance Costs	Note 8 – Deferred Debt Issuance Costs Deferred debt issuance costs consist of the following (in thousands): June 30, December 31, SLOC $ 150 $ 223 Line of Credit $ 9,943 - Total 10,093 223 Accumulated amortization (4,274 ) (73 ) Deferred debt issuance costs, net $ 5,819 $ 150 Line of Credit On February 2, 2023, the Company entered into its Line of Credit and recorded deferred debt issuance costs of approximately $9.9 million (See Note 2). During the six months ended June 30, 2023, the Company recognized amortization expense of approximately of $4.1 million in connection with the Line of Credit, which is recorded as interest expense on the accompanying condensed consolidated statement of operations. During the six months ended June 30, 2023, in connection with the $2.4 million draw down and issuance of the convertible promissory notes, the Company recognized amortization expense of approximately $0.2 million, which is recorded as interest expense on the accompanying condensed consolidated statement of operations (See Note 2). SLOC For the three months ended June 30, 2023 and 2022, in connection with its SLOC, the Company recognized amortization expense of approximately $28,000 and $26,000, respectively, which is recorded as interest expense on the accompanying condensed consolidated statements of operations. For the six months ended June 30, 2023 and 2022, in connection with its SLOC, the Company recognized amortization expense of approximately $69,000 and $29,000, respectively.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2023
Fair Value Measurements [Abstract]
Fair Value Measurements	Note 9 - Fair Value Measurements The following table classifies the Company’s liabilities measured at fair value on a recurring basis into the fair value hierarchy as of June 30, 2023 and December 31, 2022: Fair value measured at June 30, 2023 Total Quoted Significant Significant Liabilities: Convertible notes $ 1,470 $ - $ - $ 1,470 Warrant liability $ 2,721 $ - $ - $ 2,721 Fair value measured at December 31, 2022 Total Quoted Significant Significant Liabilities: Convertible notes $ 1,654 $ - $ - $ 1,654 Warrant liability $ 972 $ - $ - $ 972 For the six months ended June 30, 2023 there was an increase of approximately $1.6 million in Level 3 liabilities measured at fair value. The fair value of the convertible notes may change significantly as additional data is obtained, impacting the Company’s assumptions used to estimate the fair value of the liabilities. In evaluating this information, considerable judgment is required to interpret the data used to develop the assumptions and estimates. The estimates of fair value may not be indicative of the amounts that could be realized in a current market exchange. Accordingly, the use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts, and such changes could materially impact the Company’s results of operations in future periods. The following table presents changes in Level 3 liabilities measured at fair value for the six months ended June 30, 2023. Unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to unobservable (e.g., changes in unobservable long-dated volatilities) inputs. Convertible Warrant Balance at December 31, 2022 $ 1,654 $ 972 Conversion of October convertible notes (516 ) Issuance of convertible note in connection with Line of Credit 2,000 Change in fair value of convertible notes in connection with March waiver agreement 368 Gain on issuance of convertible note (64 ) January Notes - reclass to fair value option 1,117 Settlement in Connection with October Note (2,166 ) Conversion of October Notes (1,685 ) Settlement in Connection with LOC (5,893 ) LOC Note issuance 350 Warrants issued in connection with January promissory note 157 Warrants issued in connection with Line of Credit 5,593 Warrants issued in connection with inducement agreement 760 Warrants issued in connection with February waiver agreement 711 Fair value of warrants exercised (759 ) Other income (expense): 504 Warrants Issued in connection with Demand Notes Series F Exchange 140 Warrants Issued in connection with January Notes Series F Exchange 50 Warrants Issued in connection with October Notes Series F Exchange 639 Warrants Issued in connection with Series D to Series F Exchange 450 Warrants Issued in connection with Series F-1 956 Warrants Issued in connection with Series F-2 285 Change in fair value 6,305 (7,737 ) Balance at June 30, 2023 $ 1,470 $ 2,721 Convertible Notes During the year ended December 31, 2022, the Company issued convertible promissory notes (the “2022 Notes”). The fair value of the 2022 Notes on the issuance dates, and as of December 31, 2022 were estimated using a Monte Carlo simulation to capture the path dependencies intrinsic to their terms. The significant unobservable inputs used in the fair value measurement of the Company’s convertible notes are the common stock price, volatility, and risk-free interest rates. Significant changes in these inputs may result in significantly lower or higher fair value measurement. The Company elected the fair value option when recording its 2022 Notes and the 2022 Notes were classified as liabilities and measured at fair value on the issuance date, with changes in fair value recognized as other income (expense) on the statements of operations and disclosed in the condensed consolidated financial statements. During the six months ended June 30, 2023, seven noteholders converted a portion of their 2022 Notes into 248,981 shares of the Company’s commons stock (See Note 11). The fair value of the converted notes totaled $2.2 million. February Waiver Agreement On February 28, 2023, the Company entered into waiver agreements with holders of the 2022 Notes (See Note 11). In connection with this waiver agreement, the 2022 Notes were revalued as of the amendment date. March Waiver Agreement On March 24, 2023, the Company entered into the second waiver agreements with holders of the 2022 Notes (See Note 11). A select number of holders elected to increase the principal balance of their notes. The Company revalued the respective notes on the date prior to the amendment date, and again on the amendment date. The change in fair value related to the amendment of these 2022 Notes was approximately $0.4 million. On June 4, the Company entered into an Exchange Agreement where the 2022 Notes balance with a fair value of $0.2 million was exchanged for Series F Preferred stock. As of June 30, 2023, there was no outstanding balance related to the 2022 Notes. Line of Credit On February 3, 2023 the Company drew down $2.0 million from the Line of Credit and in accordance with the terms of the agreement issued the 2023 Note of $2.0 million. The 2023 Note had fair value at issuance of $1.9 million and the Company recorded a gain on issuance of approximately $0.1 million, which is included in other income (expense) on the accompanying condensed statement of operations. Between May 17, 2023 and May 30, 2023 the Company drew down $0.4 million from the Line of Credit and in accordance with the terms of the agreement issued the 2 nd rd As of June 30, 2023, the fair value of the 2023 Note was approximately $0.3 million. Warrants Senior Secured Notes In connection with the issuance of its senior secured notes on January 3, 2023 (See Note 11), the Company issued 41,667 warrants to purchase shares of the Company’s common stock. The warrants had a fair value at issuance of $157,000, and as of June 30, 2023 have a fair value of $35,000. Line of Credit On February 2, 2023, in connection with the issuance of its Line of Credit, the Company issued 45,000 warrants to purchase shares of its Series E preferred stock (See Note 13). The warrants had a fair value at issuance of approximately $5.6 million, and as of June 30, 2023 have a fair value of approximately $0.4 million. Warrant Inducement and Exercise Agreement During the year ended December 31, 2022, in connection with the 2022 Notes, the Company issued 362,657 warrants to purchase shares of the Company’s common stock. During the six months ended June 30, 2023, in connection with its 2022 Notes, the Company entered into a warrant inducement and exercise agreement with certain holders. Under the terms of the agreement, the holders exercised 106,764 warrants with a fair value of approximately $0.76 million and the Company issued 106,764 new warrants to purchase shares of its common stock with a fair value of $1.26 million. The Company recognized a loss on extinguishment of the warrants of approximately $0.5 million which is included in other income (expense) on the accompanying condensed statement of operations. February Waiver Agreement As consideration for the February waiver agreement, the Company issued 96,890 warrants to purchase shares of the Company’s common stock with a fair value of $0.7 million on issuance date. As of June 30, 2023, there are 459,547 warrants outstanding issued in connection with the 2022 Notes, with a fair value of approximately $0.4 million. The warrants were classified as liabilities and measured at fair value on the grant date, with changes in fair value recognized as other income (expense) on the statements of operations and disclosed in the condensed consolidated financial statements. Exchange Agreements As part of the Exchange Agreements, the Company issued 592,129 warrants to purchase shares of the Company’s common stock. The Company concluded that the Exchange Warrants are liability classified with a fair value of $1.3 million as of June 4, 2023 issuance date. As of June 30, 2023, the fair value of the Exchange Warrants is $1.0 million. Series F-1 and F-2 Issuances As part of the Series F-1 and F-2 Preferred Stock issuances, the Company issued 523,323 warrants to purchase shares of the Company’s common stock. The Company concluded that the Series F-1 and Series F-2 Warrants are liability classified with a fair value of $1.2 million as of the issuance date. As of June 30, 2023, the fair value of the Series F-1 and Series F-2 Warrants is $0.9 million. A summary of significant unobservable inputs (Level 3 inputs) used in measuring warrants on the issuance dates and as of June 30, 2023 and December 31, 2022 is as follows: Series F / F-1 / F-2 2022 Notes Warrants - Warrants - December 31, Date 6/4/2023 6/30/2023 6/30/2023 6/30/2023 12/31/2022 Dividend yield 0.0% 0.0% 0.0% 0.0% 0% Expected price volatility 50.0% 50.0% 50.0% 50.0% 48.7% Risk free interest rate 3.8% - 4.1% 4.19% - 4.26% 4.22% 4.20% 4.74% Expected term (in years) 5.0 4.3 - 4.7 4.5 4.6 0.8 Significant changes in the expected price volatility and expected term would result in significantly lower or higher fair value measurement of the warrants, respectively.

Accrued Expenses

Accrued Expenses	6 Months Ended
	Jun. 30, 2023
Accrued Expenses [Abstract]
Accrued Expenses	Note 10 - Accrued Expenses As of June 30, 2023 and December 31, 2022, the Company’s accrued expenses consisted of the following (in thousands): June 30, December 31, Payroll and related expenses $ 274 $ - Bonus - 510 Taxes 32 - Insurance - 104 Other expenses 103 7 Total $ 409 $ 621

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2023
Notes Payable [Abstract]
Notes Payable	Note 11 - Notes Payable Convertible Notes 2022 Notes On October 19, 2022, the Company issued its 2022 Notes with a principal balance of approximately $5.4 million and warrants to purchase 362,657 shares of the Company’s common stock for net proceeds of $3.5 million. The 2022 Notes were issued with a conversion price at a 54% premium to the most recent closing price, an original issue discount (“OID”) of 35%, do not bear interest, and mature upon the earlier of twelve months from the date of issuance or the closing of a change of control transaction (as defined in the 2022 Notes). The 2022 Notes are convertible into shares of the Company’s common stock at a conversion price of $29.7 per share, subject to adjustment under certain circumstances described in the notes. The 2022 Notes are secured by all of the Company’s assets (subject to exceptions for certain strategic transactions). The warrants have an exercise price of $19.32 per share and expire five years from the issuance date (subject to adjustment under certain circumstances described in the warrants). During the six months ended June 30, 2023, in connection with its 2022 Notes, the Company entered into a warrant inducement and exercise agreement with certain holders of the 2022 Notes (See Notes 7 and 13). On February 28, 2023, the Company entered into waiver agreements with holders of the 2022 Notes which extended the maturity date of the 2022 Notes from October 19, 2023 to April 18, 2024. As consideration for this agreement, the Company issued 96,890 warrants to purchase shares of the Company’s common stock (See Note 7 and 13). On March 24, 2023, the Company entered into the waiver agreements with holders of the 2022 Notes to eliminate the minimum pricing covenant as it relates to Company’s At-The-Market facility. As consideration for this agreement, the Company provided the holders with two options to choose from i) to take an additional 5% OID on their October note principal or ii) pending shareholder approval, to be issued shares of common stock with a value equal to the 5% OID, and to issue total shares of 31,724 as converted using the Nasdaq minimum price of $9.42. During the six months ended June 30, 2023, six of the note holders elected option i), and the Company increased the respective principal balance of the notes by approximately $0.15 million. The remaining noteholders elected option ii), and as of the date of this report, no shares of common stock have been issued. The Company recorded expense of $0.3 million associated with the commitment to issue shares of the Company’s common stock. On May 12, 2023, the Company entered into letter agreements (the “Inducement Agreements”) with certain of the October Investors, pursuant to which such October Investors agreed to reduce the conversion price of October Notes in an aggregate principal amount equal to $1,500,000, to $9.42 per share, which are now convertible into 161,561 shares of the Company’s common stock, representing an increase of 83,849 shares in excess of the number of shares into which such October Notes were convertible prior to the Company’s entry into the Inducement Agreements. On May 17, 2023, the Company entered into Inducement Agreements with the remaining October Investors, pursuant to which such October Investors agreed to reduce the conversion price of October Notes in an aggregate principal amount equal to $1,392,657, to $10.932 per share, which are now convertible into 127,393 shares of the Company’s common stock, representing an increase of 55,242 shares in excess of the number of shares into which such October Notes were convertible prior to the Company’s entry into the Inducement Agreements. The Company elected to account for the October Notes under the fair value option. For the Inducement Agreements that were entered into as described in Note 2, the Company accounted for the change in the terms through the fair value adjustment of $2.7 million, which is included in the $6.9 million Change in FV of Notes on the Income Statement, upon the settlement of $0.2 million principal balance of the October Notes on June 4, 2023 as part of the Exchange Agreements and $1.0 million principal balance of October Notes on June 21, 2023 based on the issuance of 248,981 shares of the Company’s Common Stock. 2023 Note On February 3, 2023, upon drawing down on the Line of Credit, the Company issued its 2023 Note totaling $2.0 million, which is due and payable 60 days from the issuance date. The 2023 Note is non-interest bearing and secured by the Company’s assets. The 2023 Note issued with the initial $2.0 million drawdown is convertible into shares of the Company’s common stock, at a conversion price per share of $30.00 per share, subject to adjustment under certain circumstances described in the 2023 Note. Notes evidencing future withdrawals, if any, will be convertible into common stock only upon the declaration of an event of default under such promissory note. On April 14, 2023, the Company entered into a First Amendment to the 2023 Note with the lender, pursuant to which the lender agreed to extend the maturity date of the 2023 Note balance until May 1, 2023 in exchange for 33,333 shares of the Company’s common stock pending shareholder approval. The 2023 Note was further amended to accrue interest at the fifteen percent (15%) per annum from the original funding date of the 2023 Note. The Company recorded a change in fair value adjustment of $0.2 million related to the commitment to issue 33,333 shares of the Company’s common stock. On May 1, 2023, the Company entered into a Second Amendment to the 2023 Note with the lender, pursuant to which the lender agreed to extend the maturity date of the 2023 Note balance until May 15, 2023 On May 15, 2023, the Company entered into a Third Amendment to the 2023 Note with the lender, pursuant to which the lender agreed to extend the maturity date of the 2023 Note until June 7, 2023 in exchange for 4,000 shares of the Company’s Series E Preferred Stock, which are convertible into 66,667 shares of the Company’s common stock pending shareholder approval. The Company recorded a change in fair value adjustment of $0.7 million related to the commitment to issue 4,000 shares of the Company’s Series E Preferred Stock. On May 16, 2023, the Company made a second draw of $0.2 million under the Line of Credit. Upon drawing down on the Line of Credit, the Company issued a second Secured Promissory Note (the “2 nd nd nd On May 26, 2023, the Company made a third draw of $0.15 million under the Line of Credit. Upon drawing down on the Line of Credit, the Company issued a third Secured Promissory Note (the “3 rd rd rd On May 26, 2023, the Company entered into that certain Fourth Amendment to the 2023 Note with the lender, pursuant to which the Company will issue to Holder a convertible promissory note in the principal amount of $0.15 million due June 2, 2023 in exchange for 4,000 shares of the Company’s Series E Preferred Stock, which are convertible into 66,667 shares of the Company’s common stock pending shareholder approval. The Company recorded a change in fair value adjustment of $0.6 million related to the commitment to issue 4,000 shares of the Company’s Series E Preferred Stock. On June 13, 2023, the Company partially redeemed the principal of the 2023 Note and fully redeemed the principal of the 2 nd rd nd rd On June 30, 2023, the Company and the LOC Lender agreed to amend the 2 nd rd Senior Secured Notes On January 3, 2023, the Company issued senior secured notes with a principal balance of approximately $1.2 million and warrants to purchase 41,667 shares of the Company’s common stock for net proceeds of $1.0 million. The senior secured notes were issued with an original issue discount of 16.7%, do not bear interest, and mature three months from the date of issuance (unless extended pursuant to the terms of the notes). Pursuant to these terms, the Notes were subsequently extended to May 3, 2023 incurring an additional 10% on Principal or $120,000. The warrants are exercisable for five years at an exercise price of $19.32, subject to adjustment under certain circumstances described in the warrants. On May 8, 2023, the Company entered into a letter agreement (the “Extension Letter”) with the lead noteholder and collateral agent for the January Notes (the “Agent”), pursuant to which we agreed to issue an aggregate of 11,833 shares of Common Stock to the holders of January Notes in exchange for the extension of the maturity date thereof until May 15, 2023. On May 15, 2023, the Agent agreed to grant us an additional extension of the maturity date thereof until May 23, 2023 in exchange for the issuance by us to the holders of January Notes, on a pro rata basis, of 66,667 shares of our Common Stock, pending shareholder approval. Subsequently, on May 23, 2023, the Agent agreed to grant us an extension of the maturity date thereof until May 31, 2023 in exchange for the issuance by us to the January Investors, on a pro rata basis, of 25,000 shares of our Common Stock, pending shareholder approval. Thereafter, on May 31, 2023, the Agent for the January Notes agreed to grant us an extension of the maturity date thereof until June 12, 2023 in exchange for the issuance by us to the January Investors, on a pro rata basis, of 100,000 shares of our Common Stock, pending shareholder approval. With the completion of the Extension Letter and additional extensions, the Company concluded that a troubled debt restructuring did not occur, but an extinguishment of the outstanding senior secured notes occurred. Subsequent to the extinguishment, the Company concluded to account for the senior secured notes using the fair value option. The Company recorded an extinguishment loss of $2.2 million. The loss was comprised of the fair value of the shares of Common Stock on the dates issued to extend the maturity date as discussed above. On June 4, 2023, $0.2 million of the outstanding senior secured notes was settled as part of the Exchange Agreements described below. The Company accounted for the settlement as an extinguishment that resulted in a gain being recognized of $0.1 million and resulted in $0.1 million being recorded as Series F convertible preferred stock and $0.1 million being recorded as part of the warrant liability. On June 30, 2023, the Company and the remaining January Investors agreed to extend the maturity date of the January Notes until July 31, 2023, in exchange for 41,667 shares of our Common Stock pending approval by shareholders. The Company recorded a change in fair value adjustment of $0.3 million based on the fair value of the 41,667 shares of Common Stock. As of June 30, 2023, the fair value of the outstanding senior secured notes approximated the principal balance of $1.1 million. The secured notes and warrants were not registered under the Securities Act of 1933, as amended (the “Securities Act”) or the securities laws of any state and were offered and sold in reliance upon the exemption from registration afforded by Section 4(a)(2) under the Securities Act and Regulation D promulgated thereunder and corresponding provisions of state securities laws, which exempt transactions by an issuer not involving any public offering. The Investors are “accredited investors” as such term is defined in Regulation D promulgated under the Securities Act.

Stockholders_ Equity

Stockholders’ Equity	6 Months Ended
	Jun. 30, 2023
Stockholders’ Deficit [Abstract]
Stockholders’ Equity	Note 12 – Stockholders’ Equity Preferred Stock As of June 30, 2023 and December 31, 2022, there were 50,000,000 authorized shares of the Company’s preferred stock, par value $0.0001 . Series A Preferred Sock As of June 30, 2023 and December 31, 2022, 251 shares of Series A preferred stock are issued and outstanding. Series B Preferred Stock As of June 30, 2023 and December 31, 2022, 1,443 shares of Series B preferred stock are issued and outstanding. Series C Preferred Stock As of June 30, 2023 and December 31, 2022, 500,756 shares of Series C preferred stock are issued and outstanding. Series D Preferred Stock On July 8, 2022, the Company’s Board of Directors authorized 7,000 shares of Series D preferred stock with a par value of $0.0001 per share. Each preferred share of Series D preferred stock has a stated valued of $16.67 per share, is convertible into shares of the Company’s common stock at an initial conversion price of $78.00 per share, and is entitled to a dividend of 12% per annum. The cumulative dividends shall be paid in common stock based on the conversion price in effect on the applicable conversion date. All accrued but unpaid dividends on shares of Series D preferred stock shall increase the stated value of such shares. The Company may redeem all, but not less than all, of the Series D preferred stock for cash, at a price per share of Series D preferred stock equal to 125% of the stated value. The Series D preferred stock has no voting rights. In July 2022, the Company issued 1,058 shares of Series D preferred stock for approximately $1.1 million. As of June 30, 2023 and December 31, 2022, zero and 1,058 shares of Series D preferred stock are issued and outstanding. 1,058 shares of Series D preferred stock were exchanged for Series F Preferred Stock and Exchange Warrants as part of the Exchange Agreements during June 2023. In connection with the issuance of the 1,058 shares of Series D preferred stock, the Company issued 13,568 equity-classified warrants to purchase shares of the Company’s common stock with an exercise price of $78.00 per share. The proceeds from the Series D preferred stock were allocated between the warrants and the Series D preferred stock based on their relative fair values. The Company entered into a Registration Rights Agreement (“RRA”) with the holders of the Series D preferred stock, whereby the Company was to use its best efforts to file a registration statement registering the resale of the shares of common stock issuable upon conversion of the Series D preferred stock and upon exercise of the warrants within thirty (30) calendar days following the closing of the Series D preferred stock offering. The Company was to use its best efforts to have the registration statement declared “effective” within ninety (90) calendar days from closing, or one hundred and twenty (120) from closing in the event the registration statement is reviewed by the SEC. If the Company fails to meet these requirements, the RRA states that the Company shall pay to each holder an amount in cash, as partial liquidated damages and not as a penalty, equal to the product of 1.0% multiplied by the aggregate subscription amount paid by such holder pursuant to the purchase agreement, up to an aggregate of 10% of the aggregate subscription amount paid by such holder pursuant to the purchase agreement for all such liquidated damages. Using the guidance provided by ASC 825-20 Financial Instruments, the Company determined that the RRA should be accounted for as a separate unit of account from the Series D preferred stock. Accordingly, under ASC 825-20, a financial instrument that is both within the scope of ASC 825-20 and subject to a registration payment arrangement shall be recognized and measured in accordance with ASC 825-20 without regard to the contingent obligation to transfer consideration pursuant to the registration payment arrangement. The RRA called for the Company to file a registration statement by August 25, 2022 and declare it effective within 90 days of July 26, 2022. The Company filed its registration statement on November 17, 2022, and the holders of the Series D preferred stock waived the related registration rights penalty of approximately $2,400. The Series D preferred stock and warrants sold were not registered under the Securities Act of 1933, as amended (the “Securities Act”) or the securities laws of any state and were offered and sold in reliance on the exemption from registration afforded by Section 4(a)(2) under the Securities Act and Regulation D promulgated thereunder and corresponding provisions of state securities laws, which exempt transactions by an issuer not involving any public offering. The holders of Series D preferred stock are “accredited investors” as such term is defined in Regulation D promulgated under the Securities Act. During the six months ended June 30, 2023, the Company filed the first amendment to its Series D preferred stock, which modifies the conversion price of the Series D preferred stock from $78.00 to $30.00 per share. The modification increased the fair value of the Series D preferred stock by approximately $6,000, which the Company recorded as a deemed dividend. Series E Preferred Stock On February 1, 2023, the Company’s Board of Directors authorized 77,000 shares of Series E preferred stock with a par value of $0.0001 per share, in connection with its 2023 Line of Credit. Each share of Series E Preferred Stock is convertible into 1,000 shares of the Company’s common stock at the option of the holders. The holders of the Series E preferred stock shall receive dividends on an as converted basis together with the holders of the Company’ common stock. The Series E preferred stock has no voting rights and does not have a preference upon any liquidation, dissolution or winding-up of the Company. Holders of Series E preferred stock are prohibited from converting shares of Series E preferred stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be initially set at 4.99% and thereafter adjusted by the holder to a number between 4.99% and 9.99%) of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. In addition, in the event a conversion of Series E preferred stock would result in the holder owning more than 19.99% of the Company’s outstanding shares of common stock, the number of shares of common stock that may be issued upon such conversion of Series E preferred stock, shall be limited to 19.99% of the Company’s outstanding shares of common stock on that date, unless stockholder approval is obtained by the Company to issue a number of shares of common stock exceeding the limit. On February 2, 2023, in connection with its Line of Credit, the Company issued 5,000 shares of Series E Preferred Stock as a commitment fee with a fair value of $1.45 million. In addition, the Company agreed to issue an additional 5,000 shares of Series E preferred stock on both the first and second anniversary date of the Line of Credit, or 10,000 shares on the first anniversary, if the Company does not elect to extend the maturity date of the Line of Credit. The fair value of the additional 10,000 shares of Series E preferred stock on the issuance date totaled $2.9 million. The Company recorded the total fair value of $4.35 million as additional paid-in capital with the offsetting increase to deferred debt issuance costs. The deferred debt issuance costs will be amortized over the term of the Line of Credit. As of June 30, 2023, following Series E conversions, zero shares of Series E preferred stock are issued and outstanding. There were no shares of Series E preferred stock issued and outstanding as of December 31, 2022. Series F Preferred Stock On June 4, 2023, the Company entered into Exchange Agreements: (i) with the October Investors for the exchange of October Notes in the aggregate principal amount of $2.6 million for 2,622 shares of the Company’s newly created Series F Convertible Preferred Stock (“Series F Preferred Stock”), in the aggregate; (ii) with the January Investors for the exchange of January Notes in the aggregate principal amount of $0.2 million for 206 shares of Series F Preferred Stock, in the aggregate; (iii) with the Demand Noteholders for the exchange of Demand Notes in the principal amount of $0.6 million for 576 shares of Series F Preferred Stock, in the aggregate; and (iv) with the purchasers of the Company’s Series D Preferred Stock for the exchange of 1,197 shares of Series D Preferred Stock for 1,847 shares of Series F Preferred Stock, in the aggregate. In addition, in connection with the Exchange Agreements, the Company issued new five-year warrants to purchase an aggregate of 592,129 shares of Common Stock (the “Exchange Warrants”) to the October Investors, the January Investors, and the purchasers of the Company’s Series D Preferred Stock. The Exchange Warrants are exercisable at an exercise price of $8.868 per share of Common Stock, subject to certain adjustments as set forth in the Exchange Warrants. The holders may exercise the Exchange Warrants on a cashless basis if the shares of our Common Stock underlying the Exchange Warrants are not then registered pursuant to an effective registration statement. The Company concluded that the Exchange Warrants are liability classified. For the October Investors, the total fair value of Series F Preferred Stock and Warrant Liability issued was $1.7 million ($1.1 million for Series F Preferred Stock and $0.6 million for Warrant Liability). For the January Investors, the total fair value of Series F Preferred Stock and Warrant Liability issued was $0.13 million ($0.1 million for Series F Preferred Stock and $0.03 million for the Warrant Liability). For the Demand Note holders, the total fair value of Series F Preferred Stock and Warrant Liability issued was $0.4 million ($0.2 million for Series F Preferred Stock and $0.2 million for the Warrant Liability). For the purchasers of the Company’s Series D Preferred Stock, the Company accounted for the exchange as an extinguishment of the Series D Preferred Stock. The Company recorded the total fair value of Series F Preferred Stock and Warrant Liability of $1.2 million ($0.7 million for Series F Preferred Stock and $0.5 million for the Warrant Liability) and the difference of $0.5 million with the $0.7 million carrying value of the Series D Preferred Stock as a deemed dividend and reduction to additional-paid-in-capital. Series F-1 Preferred Stock On June 13, 2023, the Company entered into the Purchase Agreement with the “Purchasers, pursuant to which, at the closing of the transactions contemplated by the Closing, the Purchasers agreed to purchase an aggregate of 3,583 shares of the Company’s newly created Series F-1 Convertible Preferred Stock (“Series F-1 Preferred Stock”) for an aggregate purchase price of approximately $2.3 million. In addition, in connection with the issuance of the Series F-1 Preferred Stock, the Purchasers will receive five-year warrants to purchase an aggregate of 398,377 shares of Common Stock (defined below) (the “Series F-1 Warrants”). The Series F-1 Warrants will be exercisable at an exercise price of $8.994 per share of the Company’s Common Stock, subject to certain adjustments as set forth in the Series F-1 Warrants. The holders may exercise the Series F-1 Warrants on a cashless basis if the shares of our Common Stock underlying the Series F-1 Warrants are not then registered pursuant to an effective registration statement. The obligations of the Company and the Purchasers to consummate the transactions contemplated by the Purchase Agreement are subject to the satisfaction on or prior to the Closing of customary closing conditions. The Company allocated the proceeds of $2.3 million to the liability classified Warrants with a fair value of $0.9 million and the remaining proceeds of $1.4 million to the Series F-1 Preferred Stock. Series F-2 Preferred Stock Offering On June 14, 2023, the Company entered into a F-2 Purchase Agreement with the F-2 Purchasers pursuant to which, at the closing of the transactions contemplated by the F-2 Closing, the F-2 Purchasers agreed to purchase an aggregate of 1,153 shares of the Company’s newly created the Series F-2 Preferred Stock for an aggregate purchase price of approximately $0.7 million. In addition, in connection with the issuance of the Series F-2 Preferred Stock, the F-2 Purchasers will receive five-year warrants to purchase an aggregate of 124,946 shares of Common Stock (defined below) (the “F-2 Warrants”). The F-2 Warrants will be exercisable at an exercise price of $9.228 per share of Common Stock, subject to certain adjustments as set forth in the F-2 Warrants. The holders may exercise the F-2 Warrants on a cashless basis if the shares of our Common Stock underlying the F-2 Warrants are not then registered pursuant to an effective registration statement. The obligations of the Company and the F-2 Purchasers to consummate the transactions contemplated by the F-2 Purchase Agreement are subject to the satisfaction on or prior to the F-2 Closing of customary closing conditions. The Company allocated the proceeds of $0.7 million to the liability classified the F-2 Warrants with a fair value of $0.3 million and the remaining proceeds of $0.4 million to the Series F-2 Preferred Stock. Common Stock Change in Authorized Shares On December 22, 2022, the Company’s Board of Directors approved increasing the Company’s authorized shares of common stock from 200,000,000 to 800,000,000 shares. Reverse Stock Split On August 11, 2023, the Company’s Board of Directors authorized a reverse stock split (‘Reverse Stock Split”) at an exchange ratio of one (1) share of common stock for every sixty (60) shares of common stock. The Reverse Stock Split was effective on August 15, 2023, such that every sixty (60) shares of common stock have been automatically converted into one (1) share of common stock. The Company did not issue fractional certificates for post-reverse split shares in connection with the Reverse Stock Split. Rather, all shares of common stock that were held by a stockholder were aggregated and each stockholder was entitled to receive the number of whole shares resulting from the combination of the shares so aggregated. Any fractions resulting from the Reverse Stock Split computation were rounded up to the next whole share. Warrant Exercises During the six months ended June 30, 2023, the Company issued 106,764 shares of its common stock in connection with the exercise of 106,764 warrants, receiving net proceeds of approximately $2.06 million at a weighted average price of $19.30 per share. During the six months ended June 30, 2023, the Company issued 2,493 shares of its common stock in connection with the exercise of 2,778 penny warrants. ATM Offering As of June 30, 2023, the Company has received net proceeds on sales of 211,667 shares of common stock under its ATM Offering (See Note 2) of approximately $2.1 million (after deducting $0.1 million in commissions and expenses) at a weighted average price of $10.38 per share. Restricted Stock During the six months ended June 30, 2023, the Company issued 500,000 shares of its common stock in connection with vested restricted stock units.

Stock-Based Compensation, Stock

Stock-Based Compensation, Stock Options, Restricted Stock Units and Warrants	6 Months Ended
	Jun. 30, 2023
Stock-Based Compensation, Restricted Stock and Stock Options [Abstract]
Stock-Based Compensation, Stock Options, Restricted Stock Units and Warrants	Note 13 – Stock-Based Compensation, Stock Options, Restricted Stock Units and Warrants: On December 22, 2022, the Company adopted its 2022 Long-Term Incentive Plan (the “2022 Plan”). Under the 2022 Plan, there are 70,000 shares of the Company’s common stock available for issuance and the 2022 Plan has a termination date of October 31, 2032. The available shares in the 2022 Plan will automatically increase on the first trading day in January of each calendar year during the term of 2022 Plan, commencing with January 2023, by such number of shares of common stock as are necessary so that the total number of shares reserved for issuance under the 2022 Plan shall be equal to 19.9% of the total number of outstanding shares of common stock, determined on a fully diluted basis as of the applicable trading date (the “Stipulated Percentage”); (b) our Board of Directors may act prior to January 1 st On December 16, 2020, the Company adopted its 2020 Long-Term Incentive Plan (the “2020 Plan”). Under the 2020 Plan, there are 88,889 shares of the Company’s common stock available for issuance and the 2020 Plan has a term of 10 years. The available shares in the 2020 Plan will automatically increase on the first trading day in January of each calendar year during the term of this Plan, commencing with January 2021, by an amount equal to the lesser of (i) five percent (5%) of the total number of shares of common stock issued and outstanding on December 31 of the immediately preceding calendar year, (ii) 16,667 shares of common stock or (iii) such number of shares of common stock as may be established by the Company’s Board of Directors. The Company grants equity-based compensation under its 2020 Plan and its 2016 Equity Incentive Plan (the “2016 Plan”). The 2020 Plan and 2016 Plan allows the Company to grant incentive and nonqualified stock options, and shares of restricted stock to its employees, directors and consultants. On June 14, 2019, the Board of Directors of the Company approved increasing the number of shares allocated to the Company’s 2016 Equity Incentive Plan from 91,667 to 122,222. Under the 2016 Plan and the 2020 Plan, upon the exercise of stock options and issuance of fully vested restricted common stock, shares of common stock may be withheld to satisfy tax withholdings. The Company intends to net settle certain employee options to ensure adequate authorized shares under the Incentive Plan. Stock-based compensation: The Company recognized total expenses for stock-based compensation during the six months ended June 30, 2023 and 2022, which are included in the accompanying statements of operations, as follows (in thousands): Three months ended Six months ended 2023 2022 2023 2022 Research and development expenses $ 45 $ 445 $ 104 $ 500 Selling, general and administrative expenses 87 1,003 209 2,031 Total stock-based compensation $ 132 $ 1,448 $ 313 $ 2,531 Stock Options: The Company provides stock-based compensation to employees, directors and consultants under both the 2016 and 2020 Plans. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option pricing model. The Company historically has been a private company and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The risk-free interest rate is determined by referencing the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. A summary of activity under the 2016 and 2020 Plans for the six months ended June 30, 2023 is as follows: Shares Weighted Weighted Aggregate Outstanding at December 31, 2021 Granted Canceled Forfeited Outstanding at December 31, 2022 159,295 $ 153.35 6.5 $ 26,188 Forfeited (1,516 ) $ 196.86 - Outstanding at June 30, 2023 157,779 $ 157.47 6.0 $ - Exercisable at June 30, 2023 142,884 $ 167.85 5.7 $ - Restricted stock units: A summary of the Company’s restricted stock activity during the six months ended June 30, 2023 is as follows: Number of Weighted Unvested at December 21, 2022 10,483 $ 82.02 Vested (3,344 ) $ 104.04 Unvested at June 30, 2023 7,139 $ 71.68 Warrants: A summary of the Company’s warrant (excluding penny warrants) activity during the six months ended June 30, 2023 is as follows: Shares Weighted Weighted Aggregate Outstanding at December 31, 2022 461,066 $ 44.88 4.5 $ - Issued 1,405,797 $ 11.42 4.7 Exercised (106,768 ) $ 19.20 - Outstanding at June 30, 2023 1,760,095 $ 18.96 4.7 $ - 2023 Liability Classified Warrants Senior Secured Note During the six months ended June 30, 2023, in connection with the issuance of its senior secured notes on January 3, 2023 (See Note 11), the Company issued 41,667 warrants to purchase shares of the Company’s common stock with an exercise price of $19.30 per share. The warrants expire 5 years from the issuance date. Line of Credit During the six months ended June 30, 2023, in connection with its Line of Credit, the Company issued 45,000 Series E warrants to purchase shares of its Series E preferred stock with an exercise price of $30.00 per share multiplied by 16.67, and subject to adjustment under certain circumstances described in the warrant. (See Note 11). The warrants expire 5 years from the issuance date. 2022 Notes During the year ended December 31, 2022, in connection with the 2022 Notes, the Company issued 362,657 warrants to purchase shares of the Company’s common stock. The warrants have an exercise price of $19.30 per share and expire five years from the issuance date. During the six months ended June 30, 2023, in connection with its 2022 Notes, the Company entered into a warrant inducement and exercise agreement with certain holders. Under the terms of the agreement, the holders exercised 106,764 warrants, and the Company issued 106,764 new warrants to purchase shares of its common stock with an exercise price of $19.30 per share. The warrants expire 5 years from the issuance date. On February 28, 2023, the Company entered into waiver agreements with holders of the 2022 Notes and issued 96,894 warrants to purchase shares of the Company’s common stock with an exercise price of $19.30 per share. Exchange Warrants, F-1 Warrants, and F-2 Warrants In connection with the Exchange Agreements, the Company issued new five-year warrants to purchase an aggregate of 592,137 shares of Common Stock (the “Exchange Warrants”) to the October Investors, the January Investors, and the purchasers of the Company’s Series D Preferred Stock. The Exchange Warrants are exercisable at an exercise price of $8.868 per share of Common Stock, subject to certain adjustments as set forth in the Exchange Warrants. The holders may exercise the Exchange Warrants on a cashless basis if the shares of our Common Stock underlying the Exchange Warrants are not then registered pursuant to an effective registration statement. The Company concluded that the Exchange Warrants are liability classified. In connection with the issuance of the Series F-1 Preferred Stock, the Purchasers will receive five-year Warrants to purchase an aggregate of 398,379 shares of Common Stock. The Warrants will be exercisable at an exercise price of $8.994 per share of the Company’s Common Stock, $0.0001 par value per share, subject to certain adjustments as set forth in the Warrants. The holders may exercise the Warrants on a cashless basis if the shares of our Common Stock underlying the Warrants are not then registered pursuant to an effective registration statement. The obligations of the Company and the Purchasers to consummate the transactions contemplated by the Purchase Agreement are subject to the satisfaction on or prior to the Closing of customary closing conditions. In connection with the issuance of the Series F-2 Preferred Stock, the F-2 Purchasers will receive five-year warrants to purchase an aggregate of 124,948 shares of Common Stock. The F-2 Warrants will be exercisable at an exercise price of $9.228 per share of Common Stock, subject to certain adjustments as set forth in the F-2 Warrants. The holders may exercise the F-2 Warrants on a cashless basis if the shares of our Common Stock underlying the F-2 Warrants are not then registered pursuant to an effective registration statement. The obligations of the Company and the F-2 Purchasers to consummate the transactions contemplated by the F-2 Purchase Agreement are subject to the satisfaction on or prior to the F-2 Closing of customary closing conditions. 2022 Equity Classified Warrants Hudson Pacific Properties, L.P. On August 12, 2022, the Company entered into two Purchase Orders (PO’s) with Hudson Pacific Properties, L.P. (“Hudson”) for the purchase of the Company’s Smart Window Inserts™ (“Inserts”). Hudson is a unique provider of end-to-end real estate solutions for tech and media tenants. The PO’s have a value of $85,450 and represent the first orders the Company has received prior to the launch of its Inserts. Delivery and installation are expected to begin in the fourth quarter of 2023. On August 12, 2022, as additional consideration for the PO’s, the Company issued a warrant to Hudson to purchase 5,000 shares of the Company’s common stock at $45.00 per share. The warrant has a five-year life and expires on August 12, 2027. Because Hudson is a customer, the Company accounts for the PO’s and warrants under Accounting Standards Codification (“ASC”) 606 Revenue Recognition The Company accounts for the equity-classified warrant as consideration payable to a customer under ASC 606, as it relates to the future purchase of the Inserts. Pursuant to ASC 718 Compensation – Stock Compensation (“ ”) SLOC In connection with the SLOC, on March 17, 2022 the Company issued a warrant for 3,333 shares of common stock with an exercise price of $120.00, and a total fair value of approximately $223,000. This amount is included in the accompanying consolidated balance sheet as deferred debt issuance costs (See Note 8).

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies [Abstract]
Commitments and Contingencies	Note 14 – Commitments and Contingencies Leases Oregon State University On March 8, 2016, the Company entered into a lease agreement with Oregon State University, to lease office and laboratory space located at HP Campus Building 11, 1110 NE Circle Blvd, Corvallis, Oregon, for approximately $400 monthly. On July 1, 2016, the Company entered into the first amendment to the lease agreement which increased the monthly lease expense to approximately $1,200. On October 1, 2017, the Company entered into a sublease agreement, which provides for additional office space and the monthly lease payment increased to approximately $1,800. The lease expired on June 30, 2018 and the Company extended the lease through June 30, 2019. The monthly lease payment increased to approximately $4,500 for the months ended June 30, 2018 through November 30, 2018, and increased to approximately $7,550 for the months ended December 31, 2018 through June 30, 2019. On January 24, 2022, the Company entered into the eighth amendment to its lease with Oregon State University which expands the lease to now include approximately 703 square feet of lab space, 768 square feet of cubicle space, 2,088 square feet of Highbay lab space, and 376 square feet of High bay storage space in a building commonly known as Building 11. Effective January 24, 2022, the quarterly operating expense will be $44,252 covering all utility and facility tooling costs. The sublease expires June 30, 2025. On January 20, 2023, the Company entered into the ninth amendment to its lease with Oregon State University which reduces the amount of cubicle space from 768 square feet to 288 square feet. Effective January 20, 2023 the quarterly operating expense is $41,323 covering all utility and facility tooling costs. Hudson 11601 Wilshire, LLC On March 4, 2021, the Company entered into a lease agreement with Hudson 11601 Wilshire, LLC, to lease 3,500 square feet of office space located in Los Angeles, California. The lease term is 39 months and expires on June 30, 2024. The monthly lease expense is as follows: ● Months 1-12 - $18,375 ● Months 13-24 - $19,018 ● Months 25-36 - $19,683 ● Months 37-39 - $20,372 The Company paid a security deposit totaling $20,373 at the lease inception date. HP Inc. On May 4, 2021, the Company entered into a lease agreement with HP Inc. to lease office and lab space located in Corvallis, Oregon. The lease term is 5 years, and the lease commencement date is April 1, 2021. The monthly lease expense is $7,388 and increases 3% on each anniversary of the lease commencement date. The Company paid a security deposit totaling $8,315. The Company has the option to extend the lease for an additional 5 years. On January 26, 2022, the Company entered into the first amendment to its lease with HP Inc., which amends the lease commencement date to January 26, 2022 and the lease expiration date to January 31, 2027. Pacific N.W. Properties, LLC On October 5, 2021, the Company entered into a lease agreement with Pacific N.W. Properties, LLC to lease 26,963 square feet of warehouse, manufacturing, production and office space located in Salem Oregon. The commencement date of the lease is October 1, 2021, the lease term is 62 months and expires on November 30, 2026. On December 9, 2021, the Company entered into the first amendment to its lease agreement with Pacific N.W. Properties, LLC. The Company and the Lessor entered into the Lease Termination Agreement on April 7, 2023. The Lease Termination Agreement set forth a termination fee of $0.1 million as well as required the forfeiture of the security deposit of $0.15 million from the original lease agreement. The Company was required to vacate by April 30, 2023 as well as cover all utilities through that day. As of June 30, 2023, the Company had operating lease liabilities of approximately $0.8 million and right-of-use assets of approximately $0.8 million, which are included in the condensed balance sheet. The components of lease expense were as follows: Three Months Ended Six Months Ended 2023 2022 2023 2022 Operating leases: Operating lease cost $ 126 $ 190 $ 316 $ 380 Variable lease cost (9 ) 11 49 16 Operating lease expense $ 117 $ 201 $ 365 $ 396 Supplemental cash flow information related to leases were as follows: Three Months Ended Six Months Ended 2023 2022 2023 2022 Operating cash flows - operating leases $ 119 $ 189 $ 311 $ 341 Right-of-use assets obtained in exchange for operating lease liabilities $ - $ - $ - $ 2,336 Weighted-average remaining lease term – operating leases (in years) 1.7 3.7 1.7 3.7 Weighted-average discount rate – operating leases 12.0 % 12.0 % 12.0 % 12.0 % As of June 30, 2023, future minimum payments are as follows (in thousands): Operating Leases Six months ended December 31, 2023 $ 392 Year ended December 31, 2024 405 Year ended December 31, 2025 194 Year ended December 31, 2026 100 Year ended December 31, 2027 9 Total 1,100 Less present value discount (261 ) Operating lease liabilities $ 839 During the three months ended June 30, 2023 and 2022, the Company recognized rent expense of approximately $0.2 million and $0.2 million, respectively. During the six months ended June 30, 2023 and 2022, the Company recognized rent expense of approximately $0.4 million and $0.2 million, respectively. On April 27, 2023 the Company terminated the Pacific NW lease and exited the building on May 10 th Litigation From time to time, the Company is also involved in various other claims and legal actions that arise in the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, the Company does not believe that the ultimate resolution of these actions will have a material adverse effect on its financial position, results of operations, liquidity or capital resources. Future litigation may be necessary to defend ourselves and our partners by determining the scope, enforceability and validity of third party proprietary rights or to establish the Company’s proprietary rights. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	Note 15 – Subsequent Events The Company has evaluated all subsequent events through the date of filing, August 24, 2023, of this Quarterly Report on Form 10-Q with the SEC, to ensure that this filing includes appropriate disclosure of events both recognized in the condensed consolidated financial statements as of June 30, 2023, and events which occurred after June 30, 2023, but which were not recognized in the financial statements. The Company has determined that there were no subsequent events which required recognition, adjustment to or disclosure in the financial statements. January Note Exchange Agreement On July 10, 2023, the Company and one of the remaining January Investors entered into a Forbearance Agreement (the “Forbearance Agreement”), which was subsequently amended by a First Amendment to the Forbearance Agreement on July 14, 2023 (the “First Amendment”). As amended by the First Amendment, the Forbearance Agreement provides that such January Investor shall forbear the exercise of its rights and remedies due to certain events of defaults under the January Note, including payment, until December 31, 2023, in exchange for a non-refundable payment of $100,000 in the form of a promissory note due December 31, 2023 (the “New Note”), which the terms of the New Note are under negotiation, and the payment of such January Investor’s attorneys’ fees and related costs up to $20,000. On July, 11, 2023, such January Investor agreed with the Company to accept 152,085 shares of the Company’s common stock as payment in full of their January Note, which such obligations were approximately $931,000. On July 14, 2023, another of the remaining January Investors agreed with the Company to accept 25,143 shares of common stock as payment in full of their January Note, which such obligations were approximately $132,000. On August 2, 2023, the Company entered into an exchange agreement with the remaining January Investor to exchange their January Note, with a balance of approximately $52,000, for 12,374 shares of common stock as payment in full of their January Note. Following the above, there are no January Notes outstanding. Equity Line of Credit On July 20, 2023, the Company entered into a Common Stock Purchase Agreement (the “ELOC Purchase Agreement”) with a purchaser (the “ELOC Purchaser”), whereby the Company has the right, but not the obligation, to sell to the ELOC Purchaser, and the ELOC Purchaser is obligated to purchase, up to an aggregate of $50 million of newly issued shares (the “ELOC Shares”) of the Company’s common stock. The purchase price of the shares of common stock that the Company elects to sell to the ELOC Purchaser pursuant to the ELOC Purchase Agreement will be equal to ninety-seven percent (97.0%) of the lower of (i) the lowest intraday sale price of the common stock on the Company’s current trading market on the applicable purchase date and (ii) the arithmetic average of the three (3) lowest closing sale prices during the ten (10) trading days immediately preceding the applicable purchase date. There is no upper limit on the price per share that the ELOC Purchaser could be obligated to pay for the common stock under the ELOC Purchase Agreement. The Purchase Agreement prohibits the Company from directing the ELOC Purchaser to purchase any shares of our common stock if those shares, when aggregated with all other shares of our common stock then beneficially owned by the ELOC Purchaser (as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and Rule 13d-3 thereunder), would result in the ELOC Purchaser beneficially owning more than 4.99% of the outstanding common stock. As consideration for the ELOC Purchaser’s irrevocable commitment to purchase shares of common stock upon the terms of and subject to satisfaction of the conditions set forth in the ELOC Purchase Agreement, concurrently with the execution and delivery of the ELOC Purchase Agreement, we agreed to issue to the ELOC Purchaser 21,840 shares of common stock (the “Initial Commitment Shares”) and at the earlier of the date that is thirty days following the closing of the Company’s first public offering of common stock or October 16, 2023, the Company will issue up to an additional 87,417 shares of common stock as additional commitment shares (the “Additional Commitment Shares”). Subsequent to June 30, 2023 the Company received net proceeds on sales of 283,949 shares of common stock of approximately $0.5 million (after deducting $0.03 million in commissions and expenses) at a weighted average price of $1.81 per share pursuant to the ELOC Purchase Agreement. ATM Offering On July 5, 2023, the Company and the Sales Agents filed the second amendment to the Sales Agreement (the “Second Amendment to the Sales Agreement”). Pursuant to the First Amendment to the Sales Agreement, the Company may from time to time, sell up to $5.1 million in Placement Shares of the Company’s common stock through the Sales Agents in a continuous At-the-Market Offering (the Amended ATM Offering”). According to the First Amendment to the Sales Agreement, the Company will pay the Sales Agents a commission of up to 3.0% of the aggregate gross proceeds the Company receives from all sales of its common stock in the Amended ATM Offering. Subsequent to June 30, 2023 the Company received net proceeds on sales of 421,758 shares of common stock of approximately $1.59 million (after deducting $0.76 million in commissions and expenses) at a weighted average price of $3.94 per share. The additional $2.1 million of combined ATM and ELOC equity offerings have contributed to the Company maintaining Stockholder equity levels in excess of the $2.5 million Nasdaq threshold.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2023
Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Company’s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented. The condensed consolidated results of operations for the six months ended June 30, 2023 are not necessarily indicative of the results for the full year or the results for any future periods. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes for the fiscal year ended December 31, 2022 included in the Company’s Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2023.
Use of Estimates	Use of Estimates The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s condensed consolidated financial statements relate to the valuation of its business combination, senior secured convertible notes and warrants, Series F/F-1/F-2 Preferred Stock, warrants, and equity-based awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.
Significant Accounting Policies	Significant Accounting Policies For a detailed discussion about the Company’s significant accounting policies, see the Company’s December 31, 2022 financial statements included in its 2022 Annual Report.
Revenue Recognition	Revenue Recognition The Company adopted the new revenue standard, ASC 606, on March 31, 2019 using the full retrospective approach. The adoption did not have an effect on 2021 or 2020 revenue recognition or a cumulative effect on opening equity, as the timing and measurement of revenue recognition is materially the same as under ASC 605. The core principle of the new revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle: ● Step 1: Identify the contract with the customer ● Step 2: Identify the performance obligations in the contract ● Step 3: Determine the transaction price ● Step 4: Allocate the transaction price to the performance obligations in the contract ● Step 5: Recognize revenue when the company satisfies a performance obligation For contracts where the period between when the Company transfers a promised good or service to the customer and when the customer pays is one year or less, the Company has elected the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing component. The Company’s performance obligation is to provide fiber splicing services as required based on short-term work orders as work is assigned by the Customer. The Company is required to complete the description of work described in the work order and test the service provided prior to any recognition of revenue and invoicing. The short-term work orders are for very specific performance obligations which are performed from start to finish within two weeks or less, and more often, within one week. The Company is required to adhere to the rules and regulations that are outlined in the Agreement between the Company and the Customer. Cost for the work performed is outlined in the individual work orders based on the detailed description of work to be performed. All of the revenue is recognized immediately upon completion of the work in each work order. A 5% retainage will be withheld by the Customer upon payment of invoices and will be paid to the Company within one year after termination of the contract. The retainage can be utilized by Customer for any claims that may arise after work is completed up through one year after completion. Revenue recognized during the six months ended June 30, 2023 was generated by the Company’s wholly-owned subsidiary, Crown Fiber Optics Corporation, and was immaterial. No revenue was recognized by the Company during the six months ended June 30, 2022.
Financial Instruments – Credit Losses	Financial Instruments – Credit Losses Measurements of Credit Losses on Financial Instruments (“ASC 326”), which replaces the existing incurred loss model with a current expected credit loss (“CECL”) model that requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company would be required to use a forward-looking CECL model for accounts receivables, guarantees and other financial instruments. The Company adopted ASC 326 on January 1, 2023 and ASC 326 did not have a material impact on its financial statements.
Segment and Reporting Unit Information	Segment and Reporting Unit Information Operating segments are defined as components of an entity for which discrete financial information is available that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s Chief Executive Officer is determined to be the CODM. On January 3, 2023, the Company acquired Crown Fiber Optics, Corp. (see Note 1) and is currently in the process of integrating this new business line including identifying leadership, and aligning management reporting and allocation methodologies. The Company is assessing its current segment structure in conjunction with the integration efforts.
Business Combinations	Business Combinations The Company accounts for business combinations using the guidance provided by Accounting Standards Codification (“ASC”) 805, Business Combinations Accounting for business combinations requires management to make significant estimates and assumptions, especially at the acquisition date, including estimates for intangible assets. Although the Company believes the assumptions and estimates made have been reasonable and appropriate, they are based in part on historical experience and information obtained from management of the acquired companies and are inherently uncertain. Critical estimates in valuing certain intangible assets we have acquired include future expected cash flows from customer contracts. Unanticipated events and circumstances may occur that may affect the accuracy or validity of such assumptions, estimates, or actual results. The initial purchase price may be adjusted as needed per the terms of the arrangement agreement. The allocation of purchase price, including any fair value the assets acquired and liabilities assumed as of the acquisition date has not been completed. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred.
Deferred Debt Issuance Costs	Deferred Debt Issuance Costs The Company accounts for debt issuance costs related to its Line of Credit as a deferred asset which is amortized over the life of the Line of Credit. Since the Company has elected the fair value option for its convertible notes (see below), upon a draw down, a portion of the deferred asset balance will be amortized to other expense. On the issuance date of the Company’s Line of Credit, the cost related to issuance of the Series E preferred shares and the warrant to purchase Series E preferred shares was recorded as a deferred asset.
Goodwill	Goodwill The Company performs a goodwill impairment analysis on October 1 st
Convertible Notes and Notes Payable	Convertible Notes and Notes Payable In accordance with Accounting Standards Codification 825, Financial Instruments
Warrants	Warrants The Company accounted for certain common stock warrants outstanding as a liability at fair value and adjusted the instruments to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s statements of operations. The fair value of the warrants issued by the Company have been estimated using the Black Scholes Methodology. SLOC The Company accounts for its warrants related to the SLOC in accordance with ASC 815-40, Contracts in Entity’s Own Equity. Under the guidance of ASU 2015-15, Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements Purchase Order Warrants The Company accounts for its warrants issued in connection with purchase orders in accordance with ASC 606, Revenue Recognition. Compensation - Stock Compensation (“ ”)
Net Loss per Share	Net Loss per Share ASC 260, Earnings Per Share Basic net loss per share of common stock excludes dilution and is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share of common stock reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity unless inclusion of such shares would be anti-dilutive. Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share at June 30, 2023 and 2022 are as follows: June 30, 2023 2022 Series A preferred stock 3,146 3,146 Series B preferred stock 33,883 33,883 Series C preferred stock 9,346 9,346 Series F preferred stock 592,130 - Series F-1 preferred stock 398,377 - Series F-2 preferred stock 124,946 - Convertible notes 11,667 - Warrants to purchase common stock (excluding penny warrants) 1,760,095 78,787 Warrants to purchase Series E preferred stock 750,000 - Options to purchase common stock 157,779 151,892 Unvested restricted stock units 7,139 8,613 Commitment shares 783,806 - 4,632,314 285,667
Emerging Growth Company	Emerging Growth Company The Company is considered to be an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended (JOBS Act). The JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has elected to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Securities and Exchange Act of 1934.

Significant Accounting Polici_2

Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2023
Significant Accounting Policies [Abstract]
Schedule of Potentially Dilute Loss Per Share	Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share at June 30, 2023 and 2022 are as follows: June 30, 2023 2022 Series A preferred stock 3,146 3,146 Series B preferred stock 33,883 33,883 Series C preferred stock 9,346 9,346 Series F preferred stock 592,130 - Series F-1 preferred stock 398,377 - Series F-2 preferred stock 124,946 - Convertible notes 11,667 - Warrants to purchase common stock (excluding penny warrants) 1,760,095 78,787 Warrants to purchase Series E preferred stock 750,000 - Options to purchase common stock 157,779 151,892 Unvested restricted stock units 7,139 8,613 Commitment shares 783,806 - 4,632,314 285,667

Acquisitions (Tables)

Acquisitions (Tables)	6 Months Ended
	Jun. 30, 2023
Acquisitions [Abstract]
Schedule of Assets Acquired and Liabilities Assumed	The following table summarizes the allocation of the purchase price to the assets acquired and liabilities assumed for the Amerigen 7 acquisition (in thousands): Property and equipment $ 655 Intangible assets 200 Security deposits 5 Accrued expenses (529 ) Notes payable (338 ) Total identifiable assets and liabilities acquired (7 ) Goodwill 652 Total purchase consideration $ 645

Prepaid and Other Current Ass_2

Prepaid and Other Current Assets (Tables)	6 Months Ended
	Jun. 30, 2023
Prepaid and Other Current Assets [Abstract]
Schedule of Prepaid and Other Current Assets	Prepaid and other current assets consist of the following (in thousands): June 30, December 31, License fees $ 215 $ 300 Notes receivable - - Professional fees 385 - Insurance 34 142 Hudson warrant * 86 85 Other 36 63 Total $ 756 $ 590 * Fair value of warrant issued to Hudson Pacific Properties, L.P. (See Note 13)

Property & Equipment, Net (Tabl

Property & Equipment, Net (Tables)	6 Months Ended
	Jun. 30, 2023
Property & Equipment, Net [Abstract]
Schedule of Property and Equipment, Net	Property and equipment, net, consists of the following (in thousands): June 30, December 31, 2023 2022 Equipment $ 2,456 $ 1,457 Leasehold improvements 362 362 Vehicles 159 - Computers 55 52 Other 44 - Total 3,076 1,871 Less accumulated depreciation and amortization (710 ) (462 ) Property and equipment, net $ 2,366 $ 1,409

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	6 Months Ended
	Jun. 30, 2023
Intangible Assets, Net [Abstract]
Schedule of Intangible Assets, Net	Intangible assets, net, consists of the following (in thousands): June 30, December 31, 2023 2022 Patents $ 1,800 $ 1,800 Research license 375 375 Customer relationships 200 - Total 2,375 2,175 Accumulated amortization (687 ) (577 ) Intangible assets, net $ 1,688 $ 1,598
Schedule of Estimated Amortization of Intangible Assets	The following table represents the total estimated amortization of intangible assets for the five succeeding years and thereafter as of June 30, 2023 (in thousands): Estimated Six months ended December 31, 2023 $ 121 Year ended December 31, 2024 235 Year ended December 31, 2025 234 Year ended December 31, 2026 197 Year ended December 31, 2027 and thereafter 901 Total $ 1,688

Deferred Debt Issuance Costs (T

Deferred Debt Issuance Costs (Tables)	6 Months Ended
	Jun. 30, 2023
Deferred Debt Issuance Costs [Abstract]
Schedule of Deferred Debt Issuance Costs	Deferred debt issuance costs consist of the following (in thousands): June 30, December 31, SLOC $ 150 $ 223 Line of Credit $ 9,943 - Total 10,093 223 Accumulated amortization (4,274 ) (73 ) Deferred debt issuance costs, net $ 5,819 $ 150

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2023
Fair Value Measurements [Abstract]
Schedule of Fair Value on a Recurring Basis into the Fair Value Hierarchy	The following table classifies the Company’s liabilities measured at fair value on a recurring basis into the fair value hierarchy Fair value measured at June 30, 2023 Total Quoted Significant Significant Liabilities: Convertible notes $ 1,470 $ - $ - $ 1,470 Warrant liability $ 2,721 $ - $ - $ 2,721 Fair value measured at December 31, 2022 Total Quoted Significant Significant Liabilities: Convertible notes $ 1,654 $ - $ - $ 1,654 Warrant liability $ 972 $ - $ - $ 972
Schedule of Convertible Notes and Warrant Liability	Convertible Warrant Balance at December 31, 2022 $ 1,654 $ 972 Conversion of October convertible notes (516 ) Issuance of convertible note in connection with Line of Credit 2,000 Change in fair value of convertible notes in connection with March waiver agreement 368 Gain on issuance of convertible note (64 ) January Notes - reclass to fair value option 1,117 Settlement in Connection with October Note (2,166 ) Conversion of October Notes (1,685 ) Settlement in Connection with LOC (5,893 ) LOC Note issuance 350 Warrants issued in connection with January promissory note 157 Warrants issued in connection with Line of Credit 5,593 Warrants issued in connection with inducement agreement 760 Warrants issued in connection with February waiver agreement 711 Fair value of warrants exercised (759 ) Other income (expense): 504 Warrants Issued in connection with Demand Notes Series F Exchange 140 Warrants Issued in connection with January Notes Series F Exchange 50 Warrants Issued in connection with October Notes Series F Exchange 639 Warrants Issued in connection with Series D to Series F Exchange 450 Warrants Issued in connection with Series F-1 956 Warrants Issued in connection with Series F-2 285 Change in fair value 6,305 (7,737 ) Balance at June 30, 2023 $ 1,470 $ 2,721
Schedule of Significant Unobservable Inputs (Level 3 Inputs)	A summary of significant unobservable inputs (Level 3 inputs) used in measuring warrants on the issuance dates Series F / F-1 / F-2 2022 Notes Warrants - Warrants - December 31, Date 6/4/2023 6/30/2023 6/30/2023 6/30/2023 12/31/2022 Dividend yield 0.0% 0.0% 0.0% 0.0% 0% Expected price volatility 50.0% 50.0% 50.0% 50.0% 48.7% Risk free interest rate 3.8% - 4.1% 4.19% - 4.26% 4.22% 4.20% 4.74% Expected term (in years) 5.0 4.3 - 4.7 4.5 4.6 0.8

Accrued Expenses (Tables)

Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2023
Accrued Expenses [Abstract]
Schedule of Accrued Expenses	As of June 30, 2023 and December 31, 2022, the Company’s accrued expenses consisted of the following (in thousands): June 30, December 31, Payroll and related expenses $ 274 $ - Bonus - 510 Taxes 32 - Insurance - 104 Other expenses 103 7 Total $ 409 $ 621

Stock-Based Compensation, Sto_2

Stock-Based Compensation, Stock Options, Restricted Stock Units and Warrants (Tables)	6 Months Ended
	Jun. 30, 2023
Stock-Based Compensation, Restricted Stock and Stock Options [Abstract]
Schedule of Statements of Operations	The Company recognized total expenses for stock-based compensation during the six months ended June 30, 2023 and 2022, which are included in the accompanying statements of operations, as follows (in thousands): Three months ended Six months ended 2023 2022 2023 2022 Research and development expenses $ 45 $ 445 $ 104 $ 500 Selling, general and administrative expenses 87 1,003 209 2,031 Total stock-based compensation $ 132 $ 1,448 $ 313 $ 2,531
Schedule of Activity Under the 2016 and 2020 Plans	A summary of activity under the 2016 and 2020 Plans for the six months ended June 30, 2023 is as follows: Shares Weighted Weighted Aggregate Outstanding at December 31, 2021 Granted Canceled Forfeited Outstanding at December 31, 2022 159,295 $ 153.35 6.5 $ 26,188 Forfeited (1,516 ) $ 196.86 - Outstanding at June 30, 2023 157,779 $ 157.47 6.0 $ - Exercisable at June 30, 2023 142,884 $ 167.85 5.7 $ -
Schedule of Restricted Stock Activity	A summary of the Company’s restricted stock activity during the six months ended June 30, 2023 is as follows: Number of Weighted Unvested at December 21, 2022 10,483 $ 82.02 Vested (3,344 ) $ 104.04 Unvested at June 30, 2023 7,139 $ 71.68
Schedule of Warrant (Excluding Penny Warrants) Activity	A summary of the Company’s warrant (excluding penny warrants) activity during the six months ended June 30, 2023 is as follows: Shares Weighted Weighted Aggregate Outstanding at December 31, 2022 461,066 $ 44.88 4.5 $ - Issued 1,405,797 $ 11.42 4.7 Exercised (106,768 ) $ 19.20 - Outstanding at June 30, 2023 1,760,095 $ 18.96 4.7 $ -

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies [Abstract]
Schedule of Lease Expense	The components of lease expense were as follows: Three Months Ended Six Months Ended 2023 2022 2023 2022 Operating leases: Operating lease cost $ 126 $ 190 $ 316 $ 380 Variable lease cost (9 ) 11 49 16 Operating lease expense $ 117 $ 201 $ 365 $ 396
Schedule of Supplemental Cash Flow Information Related to Leases	Supplemental cash flow information related to leases were as follows: Three Months Ended Six Months Ended 2023 2022 2023 2022 Operating cash flows - operating leases $ 119 $ 189 $ 311 $ 341 Right-of-use assets obtained in exchange for operating lease liabilities $ - $ - $ - $ 2,336 Weighted-average remaining lease term – operating leases (in years) 1.7 3.7 1.7 3.7 Weighted-average discount rate – operating leases 12.0 % 12.0 % 12.0 % 12.0 %
Schedule of Future Minimum Payments	As of June 30, 2023, future minimum payments are as follows (in thousands): Operating Leases Six months ended December 31, 2023 $ 392 Year ended December 31, 2024 405 Year ended December 31, 2025 194 Year ended December 31, 2026 100 Year ended December 31, 2027 9 Total 1,100 Less present value discount (261 ) Operating lease liabilities $ 839

Organization and Description _2

Organization and Description of Business Operations (Details) - USD ($) $ / shares in Units, $ in Thousands	Jun. 14, 2023	Jun. 13, 2023	Jun. 04, 2023	Feb. 01, 2023	Jan. 03, 2023	Jun. 30, 2023	Dec. 31, 2022	Jul. 08, 2022
Organization and Description of Business Operations (Details) [Line Items]
Preferred stock conversion price	$ 9.228	$ 8.994	$ 8.868
Preferred stock, shares authorized (in Shares)						50,000,000	50,000,000
Preferred stock, par value						$ 0.0001	$ 0.0001
Cash consideration (in Dollars)					$ 650
Maximum [Member]
Organization and Description of Business Operations (Details) [Line Items]
Preferred stock conversion price							$ 78
Series D Preferred Stock [Member]
Organization and Description of Business Operations (Details) [Line Items]
Preferred stock, shares authorized (in Shares)						7,000	7,000	7,000
Preferred stock, par value						$ 0.0001	$ 0.0001	$ 0.0001
Series D Preferred Stock [Member] | Minimum [Member]
Organization and Description of Business Operations (Details) [Line Items]
Preferred stock conversion price							$ 30
Series E Preferred Stock [Member]
Organization and Description of Business Operations (Details) [Line Items]
Preferred stock, shares authorized (in Shares)				77,000		77,000	77,000
Preferred stock, par value				$ 0.0001		$ 0.0001	$ 0.0001
Common stock, shares issued (in Shares)				1,000
Series F Preferred Stock [Member]
Organization and Description of Business Operations (Details) [Line Items]
Preferred stock, shares authorized (in Shares)			9,073			9,073	9,073
Preferred stock, par value			$ 0.0001			$ 0.0001	$ 0.0001
Convertible share value (in Dollars)			$ 1,000
Series F-1 Preferred Stock [Member]
Organization and Description of Business Operations (Details) [Line Items]
Preferred stock, shares authorized (in Shares)		9,052				9,052	9,052
Preferred stock, par value		$ 0.0001				$ 0.0001	$ 0.0001
Convertible share value (in Dollars)		$ 1,000
Series F-2 Preferred Stock [Member]
Organization and Description of Business Operations (Details) [Line Items]
Preferred stock, shares authorized (in Shares)	9,052					9,052	9,052
Preferred stock, par value	$ 0.0001					$ 0.0001	$ 0.0001
Convertible share value (in Dollars)	$ 1,000

Liquidity, Financial Conditio_2

Liquidity, Financial Condition, and Going Concern (Details) - USD ($)

1 Months Ended

6 Months Ended

Jul. 05, 2023

Jun. 14, 2023

Jun. 13, 2023

Jun. 04, 2023

Jan. 03, 2023

May 30, 2023

May 26, 2023

Jun. 30, 2023

May 31, 2023

May 18, 2023

May 17, 2023

May 16, 2023

May 12, 2023

Feb. 02, 2023

Dec. 22, 2022

Mar. 17, 2022

Liquidity, Financial Condition, and Going Concern (Details) [Line Items]

Accumulated deficit

$ 104,800,000

Working capital

6,400,000

Net loss

17,000,000

Net cash used in operating activities

8,400,000

Fund amount

10,000,000

Line of credit

100,000,000

Equity line of credit

$ 50,000,000

Aggregate gross proceed percentage

3%

3%

Agreement of sales

$ 2,100,000

Weighted average price per share (in Dollars per share)

$ 3.05

Placement shares amount

$ 5,100,000

Shares of common stock (in Shares)

545,100

Net proceeds

$ 1,000,000

Line of credit

$ 150,000

$ 200,000

$ 2,000,000

Accrues interest rate

15%

Commitment fees

200,000

Accrued interest and commitment fees

$ 2,100,000

Aggregate principal amount

$ 140,804

Allocated secured promissory notes

$ 76,626,000,000

Aggregate shares (in Shares)

46,935

Preferred stock, shares issued (in Shares)

41,667

55,242

83,849

Warrants to purchase (in Shares)

124,946

592,129

592,137

70,000

Warrant liability issued

$ 1,200,000

Exercise price per share (in Dollars per share)

$ 19.32

Exercise price per share

$ 9.228

Common Stock [Member]

Liquidity, Financial Condition, and Going Concern (Details) [Line Items]

Commissions and expenses

$ 760,000

Weighted average price per share (in Dollars per share)

$ 10.38

Net proceeds

$ 1,590,000

Exercise price per share (in Dollars per share)

$ 8.994

Warrant [Member]

Liquidity, Financial Condition, and Going Concern (Details) [Line Items]

Exercise price (in Dollars per share)

$ 8.868

$ 120

Warrant liability issued

$ 500,000

Placement Shares [Member]

Liquidity, Financial Condition, and Going Concern (Details) [Line Items]

Sale of shares

5,000,000

Series F Preferred Stock [Member]

Liquidity, Financial Condition, and Going Concern (Details) [Line Items]

Preferred stock, shares issued (in Shares)

1,847

Total fair value

$ 1,200,000

Warrant liability issued

$ 700,000

200,000

Series D Preferred Stock [Member]

Liquidity, Financial Condition, and Going Concern (Details) [Line Items]

Preferred stock, shares issued (in Shares)

1,197

Deemed dividend

$ 500,000

Reduction in additional capital

700,000

Series F-1 Preferred Stock [Member]

Liquidity, Financial Condition, and Going Concern (Details) [Line Items]

Aggregate purchase shares (in Shares)

3,583

Aggregate purchase price per share

$ 2,300,000

Aggregate shares of common stock (in Shares)

398,377

Series F-2 Preferred Stock [Member]

Liquidity, Financial Condition, and Going Concern (Details) [Line Items]

Aggregate purchase price per share

$ 700,000

Aggregate shares of common stock (in Shares)

1,153

Demand Note [Member]

Liquidity, Financial Condition, and Going Concern (Details) [Line Items]

Aggregate principal amount

$ 229,877

$ 229,877

Demand Note [Member] | Series F Preferred Stock [Member]

Liquidity, Financial Condition, and Going Concern (Details) [Line Items]

Aggregate principal amount

$ 600,000

Preferred stock, shares issued (in Shares)

576

Demand Note [Member]

Liquidity, Financial Condition, and Going Concern (Details) [Line Items]

Warrant liability issued

$ 200,000

Demand Note [Member] | Series F Preferred Stock [Member]

Liquidity, Financial Condition, and Going Concern (Details) [Line Items]

Total fair value

400,000

Warrant liability issued

200,000

Line of Credit [Member]

Liquidity, Financial Condition, and Going Concern (Details) [Line Items]

Line of credit

$ 100,000,000

Withdraw amount

$ 150,000

$ 200,000

October Investors [Member]

Liquidity, Financial Condition, and Going Concern (Details) [Line Items]

Warrant liability issued

600,000

October Investors [Member] | Convertible Preferred Stock [Member]

Liquidity, Financial Condition, and Going Concern (Details) [Line Items]

Aggregate principal amount

$ 2,600,000

Convertible shares issued (in Shares)

2,622

October Investors [Member] | Series F Preferred Stock [Member]

Liquidity, Financial Condition, and Going Concern (Details) [Line Items]

Total fair value

$ 1,700,000

Warrant liability issued

1,100,000

January Investors [Member] | Warrant [Member]

Liquidity, Financial Condition, and Going Concern (Details) [Line Items]

Warrant liability issued

30,000

January Investors [Member] | Series F Preferred Stock [Member]

Liquidity, Financial Condition, and Going Concern (Details) [Line Items]

Aggregate principal amount

$ 200,000

Preferred stock, shares issued (in Shares)

206

Total fair value

$ 130,000

Warrant liability issued

$ 100,000

At-the-Market Offerings [Member]

Liquidity, Financial Condition, and Going Concern (Details) [Line Items]

Commissions and expenses

$ 100,000

Significant Accounting Polici_3

Significant Accounting Policies (Details)	6 Months Ended
	Jun. 30, 2023
Significant Accounting Policies [Abstract]
Percentage of payment invoices	5%

Significant Accounting Polici_4

Significant Accounting Policies (Details) - Schedule of Potentially Dilute Loss Per Share - shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Schedule of Potentially Dilute Loss Per Share [Abstract]
Total	4,632,314	285,667
Convertible Notes [Member]
Schedule of Potentially Dilute Loss Per Share [Abstract]
Total	11,667
Warrants to purchase common stock (excluding penny warrants) [Member]
Schedule of Potentially Dilute Loss Per Share [Abstract]
Total	1,760,095	78,787
Warrants to purchase Series E preferred stock [Member]
Schedule of Potentially Dilute Loss Per Share [Abstract]
Total	750,000
Options to purchase common stock [Member]
Schedule of Potentially Dilute Loss Per Share [Abstract]
Total	157,779	151,892
Unvested restricted stock units [Member]
Schedule of Potentially Dilute Loss Per Share [Abstract]
Total	7,139	8,613
Commitment Shares [Member]
Schedule of Potentially Dilute Loss Per Share [Abstract]
Total	783,806
Series A Preferred Stock [Member]
Schedule of Potentially Dilute Loss Per Share [Abstract]
Series of preferred stock	3,146	3,146
Series B Preferred Stock [Member]
Schedule of Potentially Dilute Loss Per Share [Abstract]
Series of preferred stock	33,883	33,883
Series C Preferred Stock [Member]
Schedule of Potentially Dilute Loss Per Share [Abstract]
Series of preferred stock	9,346	9,346
Series F Preferred Stock [Member]
Schedule of Potentially Dilute Loss Per Share [Abstract]
Series of preferred stock	592,130
Series F-1 Preferred Stock [Member]
Schedule of Potentially Dilute Loss Per Share [Abstract]
Series of preferred stock	398,377
Series F-2 Preferred Stock [Member]
Schedule of Potentially Dilute Loss Per Share [Abstract]
Series of preferred stock	124,946

Acquisitions (Details)

Acquisitions (Details) $ in Thousands	Jan. 03, 2023 USD ($)
Acquisitions [Abstract]
Cash consideration paid	$ 650
Number of employees	12
Asset acquisition term	1 year

Acquisitions (Details) - Schedu

Acquisitions (Details) - Schedule of Assets Acquired and Liabilities Assumed $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Schedule of Assets Acquired and Liabilities Assumed [Abstract]
Property and equipment	$ 655
Intangible assets	200
Security deposits	5
Accrued expenses	(529)
Notes payable	(338)
Total identifiable assets and liabilities acquired	(7)
Goodwill	652
Total purchase consideration	$ 645

Prepaid and Other Current Ass_3

Prepaid and Other Current Assets (Details) - Schedule of Prepaid and Other Current Assets - USD ($) $ in Thousands		6 Months Ended	12 Months Ended
		Jun. 30, 2023	Dec. 31, 2022
Schedule of Prepaid and Other Current Assets [Abstract]
License fees		$ 215	$ 300
Notes receivable
Professional fees		385
Insurance		34	142
Hudson warrant	[1]	86	85
Other		36	63
Total prepaid and other current assets		$ 756	$ 590
[1] Fair value of warrant issued to Hudson Pacific Properties, L.P. (See Note 13)

Property & Equipment, Net (Deta

Property & Equipment, Net (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Property & Equipment, Net [Abstract]
Depreciation expense	$ 0.1	$ 0.1	$ 0.3	$ 0.1

Property & Equipment, Net (De_2

Property & Equipment, Net (Details) - Schedule of Property and Equipment, Net - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 3,076	$ 1,871
Less accumulated depreciation and amortization	(710)	(462)
Property and equipment, net	2,366	1,409
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	2,456	1,457
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	362	362
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	159
Computers [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	55	52
Other [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 44

Intangible Assets, Net (Details

Intangible Assets, Net (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Intangible Assets, Net [Abstract]
Amortization expense	$ 0.1	$ 0.1	$ 0.1	$ 0.1

Intangible Assets, Net (Detai_2

Intangible Assets, Net (Details) - Schedule of Intangible Assets, Net - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Schedule of Intangible Assets, Net [Abstract]
Patents	$ 1,800	$ 1,800
Research license	375	375
Customer relationships	200
Total	2,375	2,175
Accumulated amortization	(687)	(577)
Intangible assets, net	$ 1,688	$ 1,598

Intangible Assets, Net (Detai_3

Intangible Assets, Net (Details) - Schedule of Estimated Amortization of Intangible Assets $ in Thousands	Jun. 30, 2023 USD ($)
Schedule of Estimated Amortization of Intangible Assets [Abstract]
Six months ended December 31, 2023	$ 121
Year ended December 31, 2024	235
Year ended December 31, 2025	234
Year ended December 31, 2026	197
Year ended December 31, 2027 and thereafter	901
Total	$ 1,688

Deferred Debt Issuance Costs (D

Deferred Debt Issuance Costs (Details) - USD ($)		3 Months Ended		6 Months Ended
	Feb. 02, 2023	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Deferred Debt Issuance Costs (Details) [Line Items]
Deferred debt issuance costs	$ 9,900,000
Amortization expense				$ 4,100,000
Convertible promissory note				2,400,000
Line of Credit [Member]
Deferred Debt Issuance Costs (Details) [Line Items]
Amortization expense				200,000
SLOC [Member]
Deferred Debt Issuance Costs (Details) [Line Items]
Amortization expense		$ 28,000,000	$ 26,000,000	$ 69,000	$ 29,000

Deferred Debt Issuance Costs _2

Deferred Debt Issuance Costs (Details) - Schedule of Deferred Debt Issuance Costs - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Schedule of Deferred Debt Issuance Costs [Abstract]
SLOC	$ 150	$ 223
Line of Credit	9,943
Total	10,093	223
Accumulated amortization	(4,274)	(73)
Deferred debt issuance costs, net	$ 5,819	$ 150

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands				1 Months Ended	6 Months Ended	12 Months Ended
	Jun. 04, 2023	Mar. 24, 2023	Feb. 03, 2023	May 30, 2023	Jun. 30, 2023	Dec. 31, 2022	May 17, 2023	May 12, 2023	Feb. 28, 2023	Feb. 02, 2023	Jan. 03, 2023
Fair Value Measurements (Details) [Line Items]
Liabilities, fair value					$ 1,600
Shares of common stock (in Shares)					248,981
Fair value converted notes totaled					$ 2,200
Change in fair value		$ 400
Fair value amount approximately					$ 161,700	$ 161,700
Company withdrew amount				$ 400
Agreement issued			$ 2,000
Shares issued (in Shares)					106,764	362,657	127,393	161,561	96,894
Fair value amount approximately					$ 400
Warrants exercised (in Shares)					106,764
Warrants [Member]
Fair Value Measurements (Details) [Line Items]
Fair value amount approximately					$ 35,000
Fair value issuance					157,000
Shares issued (in Shares)											41,667
March Waiver Agreement [Member]
Fair Value Measurements (Details) [Line Items]
Fair value amount approximately	$ 200
Line of Credit [Member]
Fair Value Measurements (Details) [Line Items]
Fair value amount approximately					300
Company withdrew amount			2,000
Fair value issuance			1,900		5,600
Other income expense			$ 100
Shares issued (in Shares)										45,000
Warrant Inducement and Exercise Agreement [Member]
Fair Value Measurements (Details) [Line Items]
Fair value amount approximately					$ 760
Shares issued (in Shares)					106,764	362,657
Common stock fair value					$ 1,260
Loss on extinguishment					500
February Waiver Agreement [Member]
Fair Value Measurements (Details) [Line Items]
Fair value amount approximately					$ 400
Shares issued (in Shares)					96,890
Common stock fair value					$ 700
Warrants outstanding (in Shares)					459,547
Exchange Agreements [Member]
Fair Value Measurements (Details) [Line Items]
Fair value amount approximately					$ 1,000
Fair value issuance	$ 1,300
Shares issued (in Shares)					592,129
Series F-1 and F-2 Issuances [Member]
Fair Value Measurements (Details) [Line Items]
Fair value amount approximately					$ 900
Fair value issuance					$ 1,200
Shares issued (in Shares)					523,323

Fair Value Measurements (Deta_2

Fair Value Measurements (Details) - Schedule of Fair Value on a Recurring Basis into the Fair Value Hierarchy - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Liabilities:
Convertible notes	$ 1,470	$ 1,654
Warrant liability	2,721	972
Fair Value, Inputs, Level 1 [Member]
Liabilities:
Convertible notes
Warrant liability
Fair Value, Inputs, Level 2 [Member]
Liabilities:
Convertible notes
Warrant liability
Fair Value, Inputs, Level 3 [Member]
Liabilities:
Convertible notes	1,470	1,654
Warrant liability	$ 2,721	$ 972

Fair Value Measurements (Deta_3

Fair Value Measurements (Details) - Schedule of Convertible Notes and Warrant Liability $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Convertible Notes [Member]
Fair Value Measurements (Details) - Schedule of Convertible Notes and Warrant Liability [Line Items]
Balance Beginning	$ 1,654
Balance Ending	1,470
Loss on extinguishment of warrant liability	(516)
Issuance of Series F preferred stock in connection with cancellation of notes	2,000
Change in fair value of convertible notes in connection with March waiver agreement	368
Gain on issuance of convertible note	(64)
January Notes - reclass to fair value option	1,117
Settlement in Connection with October Note	(2,166)
Conversion of October Notes	(1,685)
Settlement in Connection with LOC	(5,893)
LOC Note issuance	350
Warrants issued in connection with January promissory notes
Warrants issued in connection with Line of Credit
Warrants issued in connection with inducement agreement
Warrants issued in connection with February waiver agreement
Fair value of warrants exercised
Warrants Issued in connection with Demand Notes Series F Exchange
Warrants Issued in connection with January Notes Series F Exchange
Warrants Issued in connection with October Notes Series F Exchange
Warrants Issued in connection with Series D to Series F Exchange
Warrants Issued in connection with Series F-1
Warrants Issued in connection with Series F-2
Change in fair value	6,305
Warrant Liability [Member]
Fair Value Measurements (Details) - Schedule of Convertible Notes and Warrant Liability [Line Items]
Balance Beginning	972
Balance Ending	2,721
Issuance of Series F preferred stock in connection with cancellation of notes
Change in fair value of convertible notes in connection with March waiver agreement
January Notes - reclass to fair value option
Settlement in Connection with LOC
LOC Note issuance
Warrants issued in connection with January promissory notes	157
Warrants issued in connection with Line of Credit	5,593
Warrants issued in connection with inducement agreement	760
Warrants issued in connection with February waiver agreement	711
Fair value of warrants exercised	(759)
Other income (expense):	504
Warrants Issued in connection with Demand Notes Series F Exchange	140
Warrants Issued in connection with January Notes Series F Exchange	50
Warrants Issued in connection with October Notes Series F Exchange	639
Warrants Issued in connection with Series D to Series F Exchange	450
Warrants Issued in connection with Series F-1	956
Warrants Issued in connection with Series F-2	285
Change in fair value	$ (7,737)

Fair Value Measurements (Deta_4

Fair Value Measurements (Details) - Schedule of Significant Unobservable Inputs (Level 3 Inputs)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Schedule of Significant Unobservable Inputs (Level 3 Inputs) [Abstract]
Date		Dec. 31, 2022
Dividend yield		0%
Expected price volatility		48.70%
Risk free interest rate		4.74%
Expected term (in years)		9 months 18 days
Series F / F-1 / F-2 [Member]
Schedule of Significant Unobservable Inputs (Level 3 Inputs) [Abstract]
Date	Jun. 04, 2023
Dividend yield	0%
Expected price volatility	50%
Expected term (in years)	5 years
Series F / F-1 / F-2 [Member] | Minimum [Member]
Schedule of Significant Unobservable Inputs (Level 3 Inputs) [Abstract]
Risk free interest rate	3.80%
Series F / F-1 / F-2 [Member] | Maximum [Member]
Schedule of Significant Unobservable Inputs (Level 3 Inputs) [Abstract]
Risk free interest rate	4.10%
2022 Notes [Member]
Schedule of Significant Unobservable Inputs (Level 3 Inputs) [Abstract]
Date	Jun. 30, 2023
Dividend yield	0%
Expected price volatility	50%
Risk free interest rate
Expected term (in years)
2022 Notes [Member] | Minimum [Member]
Schedule of Significant Unobservable Inputs (Level 3 Inputs) [Abstract]
Risk free interest rate	4.19%
Expected term (in years)	4 years 3 months 18 days
2022 Notes [Member] | Maximum [Member]
Schedule of Significant Unobservable Inputs (Level 3 Inputs) [Abstract]
Risk free interest rate	4.26%
Expected term (in years)	4 years 8 months 12 days
Warrants - January Note [Member]
Schedule of Significant Unobservable Inputs (Level 3 Inputs) [Abstract]
Date	Jun. 30, 2023
Dividend yield	0%
Expected price volatility	50%
Risk free interest rate	4.22%
Expected term (in years)	4 years 6 months
Warrants - Series E - LOC [Member]
Schedule of Significant Unobservable Inputs (Level 3 Inputs) [Abstract]
Date	Jun. 30, 2023
Dividend yield	0%
Expected price volatility	50%
Risk free interest rate	4.20%
Expected term (in years)	4 years 7 months 6 days

Accrued Expenses (Details) - Sc

Accrued Expenses (Details) - Schedule of Accrued Expenses - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Schedule of Accrued Expenses [Abstract]
Payroll and related expenses	$ 274
Bonus		510
Taxes	32
Insurance		104
Other expenses	103	7
Total	$ 409	$ 621

Notes Payable (Details)

Notes Payable (Details) - USD ($)													1 Months Ended				3 Months Ended		6 Months Ended
	Jun. 04, 2023	Jun. 04, 2023	May 31, 2023	May 23, 2023	May 17, 2023	May 15, 2023	May 12, 2023	May 01, 2023	Apr. 14, 2023	Feb. 28, 2023	Feb. 03, 2023	Jan. 03, 2023	May 26, 2023	May 16, 2023	Mar. 24, 2023	Oct. 19, 2022	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Jun. 21, 2023	Jun. 13, 2023	May 08, 2023	Feb. 02, 2023	Dec. 31, 2022
Notes Payable (Details) [Line Items]
Principal balance	$ 600,000	$ 600,000										$ 120,000				$ 5,400,000	$ 200,000		$ 200,000
Warrants to purchase shares (in Shares)																362,657
Conversion price at premium percentage															5%	54%
Original issue discount percentage																35%
Conversion price per share (in Dollars per share)																$ 29.7
Warrants exercise price (in Dollars per share)																$ 19.32
Expiration period																5 years
Maturity date								maturity date of the 2023 Note balance until May 15, 2023		maturity date of the 2022 Notes from October 19, 2023 to April 18, 2024									maturity dates of each until July 16, 2023
Additional percentage															5%
Issue of total shares (in Shares)															31,724
Converted minimum price per share (in Dollars per share)															$ 9.42
Expense																	$ 100,000	$ 100,000	$ 300,000	$ 100,000
Principal amount					$ 1,392,657		$ 1,500,000
Price per share (in Dollars per share)					$ 10.932		$ 9.42
Shares (in Shares)					127,393		161,561			96,894							106,764		106,764						362,657
Number of excess shares (in Shares)					55,242		83,849										41,667		41,667
Fair value adjustment						$ 700,000			$ 200,000				$ 600,000						$ 2,000,000
Fair value notes																					$ 1,000,000
Agreed to issue shares (in Shares)									33,333												248,981		11,833
Total notes											$ 2,000,000
Issuance date											60 days
Common stock , per share (in Dollars per share)											$ 30
Common stock shares (in Shares)									33,333
Accrued interest percentage									15%					15%
Line of credit													150,000	$ 200,000										$ 2,000,000
Commitment to issue													200,000,000									$ 2,100,000
Commitment fee													200,000
Promissory note principal amount													$ 150
Convertible preferred stock (in Shares)																	133,333		133,333
Shares issued
Senior secured notes	200,000	200,000										$ 1,200,000					1,100,000		$ 1,100,000
Purchase warrants (in Shares)												41,667
Common stock for net proceeds												$ 1,000,000
Percentage of additional principal												10%
Warrant exercise price (in Dollars per share)												$ 19.32
Shares of common stock (in Shares)			25,000	100,000		66,667													41,667
Extinguishment loss		100,000										$ 2,200,000							$ 2,345,000
Derivative liability	$ 100,000	$ 100,000
Warrant [Member]
Notes Payable (Details) [Line Items]
Warrants to purchase shares (in Shares)																			96,890
Minimum [Member]
Notes Payable (Details) [Line Items]
Fair value adjustment															$ 2,700,000
Maximum [Member]
Notes Payable (Details) [Line Items]
Fair value adjustment															$ 6,900,000
Senior Secured Notes [Member]
Notes Payable (Details) [Line Items]
Conversion price at premium percentage												16.70%
Common stock of insurance shares (in Shares)						66,667							66,667
Notes [Member]
Notes Payable (Details) [Line Items]
Fair value notes																						$ 100,000
Waiver Agreements [Member]
Notes Payable (Details) [Line Items]
Principal balance																	$ 150,000		$ 150,000
Senior Secured Notes [Member]
Notes Payable (Details) [Line Items]
Fair value adjustment																			$ 300,000
Series E Preferred Stock [Member]
Notes Payable (Details) [Line Items]
Number of excess shares (in Shares)																	0		0
Agreed to issue shares (in Shares)																	8,000		8,000
Commitment to shares (in Shares)						4,000							4,000
Commitment to issue shares (in Shares)						4,000
Additional shares (in Shares)													4,000
Shares of preferred stock (in Shares)																			5,000
Shares issued																	$ 13,000		$ 13,000
Common Stock [Member]
Notes Payable (Details) [Line Items]
Shares of preferred stock (in Shares)																			83,333
Series F Preferred Stock [Member]
Notes Payable (Details) [Line Items]
Number of excess shares (in Shares)	1,847	1,847
Common stock shares (in Shares)	1,847
Convertible preferred stock (in Shares)	100,000	100,000
Common Class A [Member]
Notes Payable (Details) [Line Items]
Shares (in Shares)																	41,667		41,667
Senior Secured Convertible Notes [Member]
Notes Payable (Details) [Line Items]
Net proceeds																$ 3,500,000
Line of Credit [Member]
Notes Payable (Details) [Line Items]
Shares (in Shares)																								45,000
Total notes											$ 2,000,000
Line of credit																								$ 100,000,000

Stockholders_ Equity (Details)

Stockholders’ Equity (Details) - USD ($)										1 Months Ended		3 Months Ended	6 Months Ended		12 Months Ended
	Aug. 15, 2023	Aug. 11, 2023	Jun. 14, 2023	Jun. 13, 2023	Jun. 04, 2023	May 15, 2023	Apr. 14, 2023	Feb. 02, 2023	Jan. 03, 2023	Jul. 31, 2022	Mar. 17, 2022	Jun. 30, 2023	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	May 17, 2023	May 12, 2023	Feb. 01, 2023	Dec. 22, 2022	Nov. 17, 2022	Oct. 19, 2022	Jul. 08, 2022
Stockholders’ Equity (Details) [Line Items]
Preferred stock, shares authorized												50,000,000	50,000,000		50,000,000
Preferred stock, par value (in Dollars per share)												$ 0.0001	$ 0.0001		$ 0.0001
Preferred stock, shares outstanding
Preferred stock issuance (in Dollars)								$ 2,900,000						$ 1,058,000
Purchase of warrants									41,667
Exercise price per share (in Dollars per share)													$ 8.994
Cash paid (in Dollars)												$ 36,000	$ 36,000		$ 821,000
Conversion price (in Dollars per share)																					$ 29.7
Percentage of outstanding shares													19.99%
Fair value of additional capital (in Dollars)								$ 4,350,000				$ 700,000	$ 700,000
Preferred stock, shares issued												41,667	41,667			55,242	83,849
Aggregate principal shares					206
Principal amount (in Dollars)					$ 600,000				$ 120,000			$ 200,000	$ 200,000								$ 5,400,000
Aggregate shares				3,583	576								592,129
Exchange shares							33,333
Exercise price (in Dollars per share)													$ 8.868
Warrant liability issued (in Dollars)												$ 1,000	$ 1,000
Warrant liability (in Dollars)											$ 223,000,000
Warrant liability issued (in Dollars)													100,000
Series preferred stock (in Dollars)													200,000
Fair value of preferred stock (in Dollars)													161,700,000		$ 161,700,000
Warrant liability (in Dollars)													$ 1,200,000
Warrants exercise price (in Dollars per share)				$ 8.994
Preferred Stock purchase price (in Dollars)			$ 0.7
Exercise price per share (in Dollars per share)												$ 8.868	$ 8.868
Common stock, shares authorized												800,000,000	800,000,000		800,000,000
Weighted average price (in Dollars per share)												$ 1.81	$ 1.81
Restricted common stock shares Issued													500,000
Common Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Dividend percentage													12%
Commissions and expenses (in Dollars)													$ 760,000
Warrant Exercises [Member]
Stockholders’ Equity (Details) [Line Items]
Exercise warrants													106,764
Exercise of stock options and received proceeds													106,764
Net proceeds (in Dollars)												$ 2,060,000	$ 2,060,000
Vested restricted stock units													19.3
Shares issued												2,493	2,493
Exercise of penny warrants												2,778	2,778
Minimum [Member]
Stockholders’ Equity (Details) [Line Items]
Aggregate subscription percentage													1%
Common stock, shares authorized																			200,000,000
Maximum [Member]
Stockholders’ Equity (Details) [Line Items]
Aggregate subscription percentage													10%
Common stock, shares authorized																			800,000,000
Warrant Liability [Member]
Stockholders’ Equity (Details) [Line Items]
Fair value of additional capital (in Dollars)												$ 500,000	$ 500,000
ATM Offering [Member]
Stockholders’ Equity (Details) [Line Items]
Net proceeds on sales													211,667
Agreement sales (in Dollars)													$ 2,100,000
Commissions and expenses (in Dollars)													$ 100,000
Weighted average price (in Dollars per share)												$ 10.38	$ 10.38
Series A Preferred Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Preferred stock, shares authorized												300	300		300
Preferred stock, par value (in Dollars per share)												$ 0.0001	$ 0.0001		$ 0.0001
Preferred stock, shares issued												251	251		251
Preferred stock, shares outstanding												251	251		251
Series B Preferred Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Preferred stock, shares authorized												1,500	1,500		1,500
Preferred stock, par value (in Dollars per share)												$ 0.0001	$ 0.0001		$ 0.0001
Preferred stock, shares issued												1,443	1,443		1,443
Preferred stock, shares outstanding												1,443	1,443		1,443
Series C Preferred Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Preferred stock, shares authorized												600,000	600,000		600,000
Preferred stock, par value (in Dollars per share)												$ 0.0001	$ 0.0001		$ 0.0001
Preferred stock, shares issued												500,756	500,756		500,756
Preferred stock, shares outstanding												500,756	500,756		500,756
Series D Preferred Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Preferred stock, shares authorized												7,000	7,000		7,000							7,000
Preferred stock, par value (in Dollars per share)												$ 0.0001	$ 0.0001		$ 0.0001							$ 0.0001
Preferred stock, shares issued												0	0		1,058
Preferred stock, shares outstanding												0	0		1,058
Conversion price (in Dollars per share)													$ 78
Preferred stock stated value percentage													125%
Preferred stock issuance (in Dollars)										$ 1,058
Preferred stock shares (in Dollars)										$ 1,100,000
Preferred stock, share issued															1,058
Preferred stock, outstanding															1,058
Connection of issuance shares													1,058
Purchase of warrants													13,568
Exercise price per share (in Dollars per share)													$ 78
Cash paid (in Dollars)																				$ 2,400
Increased the fair value (in Dollars)													$ 6,000
Preferred stock, shares issued					1,197
Exchange shares					1,197
Series D Preferred Stock [Member] | Minimum [Member]
Stockholders’ Equity (Details) [Line Items]
Conversion price (in Dollars per share)												$ 30	$ 30
Series D Preferred Stock [Member] | Maximum [Member]
Stockholders’ Equity (Details) [Line Items]
Conversion price (in Dollars per share)												$ 78	$ 78
Series F Preferred Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Preferred stock, shares authorized					9,073							9,073	9,073		9,073
Preferred stock, par value (in Dollars per share)					$ 0.0001							$ 0.0001	$ 0.0001		$ 0.0001
Preferred stock, shares outstanding												5,251	5,251
Exchange warrants													1,058
Fair value of additional capital (in Dollars)												$ 500,000	$ 500,000
Preferred stock, shares issued					1,847
Aggregate principal amount (in Dollars)					$ 2,600,000
Aggregate principal shares					2,622
Aggregate prinicipal amount (in Dollars)					$ 200,000
Exchange shares					1,847
Warrant liability (in Dollars)													1,100,000
Preferred stock and warrant liability (in Dollars)													600,000
Warrant liability issued (in Dollars)													130,000
Series preferred stock (in Dollars)													30,000
Fair value of preferred stock (in Dollars)													400,000
Warrant liability (in Dollars)					$ 700,000								200,000
Series F Preferred Stock [Member] | Warrant Liability [Member]
Stockholders’ Equity (Details) [Line Items]
Fair value of additional capital (in Dollars)												$ 700,000	700,000
Warrant liability issued (in Dollars)													$ 1,700,000
Series E Preferred Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Preferred stock, shares authorized												77,000	77,000		77,000			77,000
Preferred stock, par value (in Dollars per share)												$ 0.0001	$ 0.0001		$ 0.0001			$ 0.0001
Preferred stock, shares issued								5,000
Preferred stock, shares outstanding												21,000	21,000
Percentage of outstanding shares													19.99%
Commitment fee with fair value (in Dollars)								$ 1,450,000
Additional shares													5,000
Fair value of additional shares								10,000
Preferred stock, shares issued												0	0
Preferred stock, shares outstanding												0	0
Vested restricted stock units						4,000
Series F-1 Preferred Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Preferred stock, shares authorized				9,052								9,052	9,052		9,052
Preferred stock, par value (in Dollars per share)				$ 0.0001								$ 0.0001	$ 0.0001		$ 0.0001
Preferred stock, shares outstanding												3,583	3,583
Aggregate shares				398,377
Aggregate purchase (in Dollars)				$ 2,300,000
Proceeds of warrant liability (in Dollars)													$ 2,300,000
Warrant fair value (in Dollars)													900,000
Remaining proceeds (in Dollars)													$ 1,400,000
Aggregate shares			1,153
Shares of common stock			124,946
Exercise price per share (in Dollars per share)			$ 9.228
Series F-2 Preferred Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Preferred stock, shares authorized			9,052									9,052	9,052		9,052
Preferred stock, par value (in Dollars per share)			$ 0.0001									$ 0.0001	$ 0.0001		$ 0.0001
Preferred stock, shares outstanding												1,153	1,153
Proceeds of warrant liability (in Dollars)													$ 700,000
Warrant fair value (in Dollars)													300,000
Remaining proceeds (in Dollars)													$ 400,000
Reverse Stock Split [Member]
Stockholders’ Equity (Details) [Line Items]
Reverse stock split	60	1
Common stock	1	60
Equity Method Investment [Member]
Stockholders’ Equity (Details) [Line Items]
Ownership percentage												4.99%	4.99%
Equity Method Investment [Member] | Minimum [Member]
Stockholders’ Equity (Details) [Line Items]
Ownership percentage												4.99%	4.99%
Equity Method Investment [Member] | Maximum [Member]
Stockholders’ Equity (Details) [Line Items]
Ownership percentage												9.99%	9.99%
Board of Directors [Member] | Series D Preferred Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Preferred stock, par value (in Dollars per share)												$ 16.67	$ 16.67
Board of Directors [Member] | Series E Preferred Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Convertible shares																		1,000
Second Anniversary [Member] | First Anniversary [Member]
Stockholders’ Equity (Details) [Line Items]
Additional shares								5,000
First Anniversary [Member]
Stockholders’ Equity (Details) [Line Items]
Additional shares								10,000

Stock-Based Compensation, Sto_3

Stock-Based Compensation, Stock Options, Restricted Stock Units and Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended		6 Months Ended	12 Months Ended
	Aug. 12, 2022	Mar. 17, 2022	Dec. 16, 2020	Jun. 30, 2023	Dec. 31, 2022	Jun. 14, 2023	Jun. 04, 2023	May 17, 2023	May 12, 2023	Feb. 28, 2023	Dec. 22, 2022	Jun. 14, 2019
Stock-Based Compensation, Stock Options, Restricted Stock Units and Warrants (Details) [Line Items]
Common stock available for issuance				592,137		124,946	592,129				70,000
Total number of outstanding shares, percentage				19.90%
Purchase of warrants				41,667				55,242	83,849
Common stock exercise price (in Dollars per share)				$ 19.3
Granted restricted stock units				45,000
Exercise price per share (in Dollars per share)				$ 30
Preferred stock exercise price (in Dollars per share)				$ 16.67
Purchase of warrants				106,764	362,657			127,393	161,561	96,894
Share price (in Dollars per share)				$ 19.3	$ 19.3					$ 19.3
Stock option of cancelled shares				106,764
Warrants exercisable price per shares (in Dollars per share)				$ 8.868
Aggregate purchase shares				398,379
Warrant exercise price (in Dollars per share)				$ 8.994
Common stock par value (in Dollars per share)				$ 0.0001	$ 0.0001
Purchase of aggregate shares				124,948
Warrant exercise price per share (in Dollars per share)				$ 9.228
First orders value (in Dollars)	$ 85,450
Warrant issued, description	as additional consideration for the PO’s, the Company issued a warrant to Hudson to purchase 5,000 shares of the Company’s common stock at $45.00 per share. The warrant has a five-year life and expires on August 12, 2027.
Fair value of warrant issuance (in Dollars)				$ 161,700	$ 161,700
Prepaid asset (in Dollars)				$ 85,450
Total fair value (in Dollars)		$ 223,000
Warrant [Member]
Stock-Based Compensation, Stock Options, Restricted Stock Units and Warrants (Details) [Line Items]
Issued a warrant shares		3,333
Exercise price (in Dollars per share)		$ 120					$ 8.868
2020 Plan [Member]
Stock-Based Compensation, Stock Options, Restricted Stock Units and Warrants (Details) [Line Items]
Common stock available for issuance			88,889
Expire term			10 years
Equity compensation plan, description			The available shares in the 2020 Plan will automatically increase on the first trading day in January of each calendar year during the term of this Plan, commencing with January 2021, by an amount equal to the lesser of (i) five percent (5%) of the total number of shares of common stock issued and outstanding on December 31 of the immediately preceding calendar year, (ii) 16,667 shares of common stock or (iii) such number of shares of common stock as may be established by the Company’s Board of Directors.
2016 Equity Incentive Plan [Member] | Minimum [Member]
Stock-Based Compensation, Stock Options, Restricted Stock Units and Warrants (Details) [Line Items]
Number of shares issued												91,667
2016 Equity Incentive Plan [Member] | Maximum [Member]
Stock-Based Compensation, Stock Options, Restricted Stock Units and Warrants (Details) [Line Items]
Number of shares issued												122,222

Stock-Based Compensation, Sto_4

Stock-Based Compensation, Stock Options, Restricted Stock Units and Warrants (Details) - Schedule of Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Schedule Of Statements Of Operations Abstract
Research and development expenses	$ 45	$ 445	$ 104	$ 500
Selling, general and administrative expenses	87	1,003	209	2,031
Total stock-based compensation	$ 132	$ 1,448	$ 313	$ 2,531

Stock-Based Compensation, Sto_5

Stock-Based Compensation, Stock Options, Restricted Stock Units and Warrants (Details) - Schedule of Activity Under the 2016 and 2020 Plans - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Schedule Of Activity Under The2016 And2020 Plans Abstract
Shares Underlying Options, Outstanding at Beginning Balance	159,295
Weighted Average Exercise Price, Outstanding at Beginning Balance	$ 153.35
Weighted Average Remaining Contractual Term (Years), Outstanding at Beginning Balance
Aggregate Intrinsic Value, Outstanding at Beginning Balance
Shares Underlying Options, Granted
Weighted Average Exercise Price, Granted
Weighted Average Remaining Contractual Term (Years), Granted
Aggregate Intrinsic Value, Granted
Shares Underlying Options, Canceled
Weighted Average Exercise Price, Canceled
Weighted Average Remaining Contractual Term (Years), Canceled
Aggregate Intrinsic Value, Canceled
Shares Underlying Options, Forfeited	(1,516)
Weighted Average Exercise Price, Forfeited	$ 196.86
Weighted Average Remaining Contractual Term (Years), Forfeited
Aggregate Intrinsic Value, Forfeited
Shares Underlying Options, Outstanding at Ending Balance	157,779	159,295
Weighted Average Exercise Price, Outstanding at Ending Balance	$ 157.47	$ 153.35
Weighted Average Remaining Contractual Term (Years), Outstanding at Ending Balance	6 years	6 years 6 months
Aggregate Intrinsic Value, Outstanding at Ending Balance		$ 26,188
Shares Underlying Options, Exercisable	142,884
Weighted Average Exercise Price, Weighted Average Exercise Price, Exercisable	$ 167.85
Weighted Average Remaining Contractual Term (Years), Exercisable	5 years 8 months 12 days
Aggregate Intrinsic Value, Exercisable

Stock-Based Compensation, Sto_6

Stock-Based Compensation, Stock Options, Restricted Stock Units and Warrants (Details) - Schedule of Restricted Stock Activity	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Schedule Of Restricted Stock Activity Abstract
Number of Shares, Unvested at Beginning Balance | shares	10,483
Weighted Average Grant-Date Fair Value, Unvested at Beginning Balance | $ / shares	$ 82.02
Number of Shares, Vested | shares	(3,344)
Weighted Average Grant-Date Fair Value, Vested | $ / shares	$ 104.04
Number of Shares, Unvested at Ending Balance | shares	7,139
Weighted Average Grant-Date Fair Value, Unvested at Ending Balance | $ / shares	$ 71.68

Stock-Based Compensation, Sto_7

Stock-Based Compensation, Stock Options, Restricted Stock Units and Warrants (Details) - Schedule of Warrant (Excluding Penny Warrants) Activity - Warrant [Member]	6 Months Ended
	Jun. 30, 2023 USD ($) $ / shares shares
Class of Warrant or Right [Line Items]
Shares Underlying Warrants, Outstanding at Beginning Balance | shares	461,066
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 44.88
Weighted Average Remaining Contractual Term (Years), Beginning Balance	4 years 6 months
Aggregate Intrinsic Value, Beginning Balance | $
Shares Underlying Warrants, Issued Beginning Balance | shares	1,405,797
Weighted Average Exercise Price, Issued Beginning Balance | $ / shares	$ 11.42
Weighted Average Remaining Contractual Term (Years), Issued Beginning Balance	4 years 8 months 12 days
Aggregate Intrinsic Value, Issued Beginning Balance | $
Shares Underlying Warrants, Exercised | shares	(106,768)
Weighted Average Exercise Price, Exercised | $ / shares	$ 19.2
Weighted Average Remaining Contractual Term (Years), Exercised
Aggregate Intrinsic Value, Exercised | $
Shares Underlying Warrants, Outstanding at Ending Balance | shares	1,760,095
Weighted Average Exercise Price, Ending Balance | $ / shares	$ 18.96
Weighted Average Remaining Contractual Term (Years), Ending Balance	4 years 8 months 12 days
Aggregate Intrinsic Value, Ending Balance | $

Commitments and Contingencies_2

Commitments and Contingencies (Details)

1 Months Ended

3 Months Ended

6 Months Ended

Dec. 09, 2021 USD ($)

May 04, 2021 USD ($)

Mar. 04, 2021

Oct. 01, 2017 USD ($)

Jul. 01, 2016 USD ($)

Mar. 08, 2016 USD ($)

Apr. 27, 2023 USD ($)

Jan. 20, 2023 USD ($) ft²

Jan. 24, 2022 USD ($)

Jun. 30, 2023 USD ($)

Jun. 30, 2022 USD ($)

Jun. 30, 2023 USD ($)

Jun. 30, 2022 USD ($)

Jun. 30, 2019 USD ($)

Nov. 30, 2018 USD ($)

Oct. 05, 2021 m²

Commitments and Contingencies (Details) [Line Items]

Operating leases rent expense

$ 1,800

$ 1,200

$ 400

$ 7,550

$ 4,500

Eighth amendment, description

the Company entered into the eighth amendment to its lease with Oregon State University which expands the lease to now include approximately 703 square feet of lab space, 768 square feet of cubicle space, 2,088 square feet of Highbay lab space, and 376 square feet of High bay storage space in a building commonly known as Building 11.

Operating expense

$ 41,323

$ 44,252

Lease term

5 years

Monthly lease expense

$ 7,388

Increases lease commencement date percentage

3%

Deposit

$ 8,315

Additional lease

5 years

Lease term

62 years

Termination fee

$ 100,000

Security deposit

$ 150,000

Operating lease liabilities

$ 800,000

$ 800,000

Right-of-use assets

$ 2,336,000

Rent expenses

$ 200,000

$ 200,000

400,000

$ 200,000

Forfeiting crowns security

$ 150,000

Additional deposit

$ 115,394

Pacific N.W. Properties, LLC [Member]

Commitments and Contingencies (Details) [Line Items]

Right-of-use assets

$ 800,000

Maximum [Member]

Commitments and Contingencies (Details) [Line Items]

Square feet | ft²

768

Minimum [Member]

Commitments and Contingencies (Details) [Line Items]

Square feet | ft²

288

Hudson 11601 Wilshire LLC [Member]

Commitments and Contingencies (Details) [Line Items]

Lease agreement description

On March 4, 2021, the Company entered into a lease agreement with Hudson 11601 Wilshire, LLC, to lease 3,500 square feet of office space located in Los Angeles, California. The lease term is 39 months and expires on June 30, 2024. The monthly lease expense is as follows:   ● Months 1-12 - $18,375   ● Months 13-24 - $19,018   ● Months 25-36 - $19,683   ● Months 37-39 - $20,372 The Company paid a security deposit totaling $20,373 at the lease inception date.

Pacific N.W. Properties, LLC [Member]

Commitments and Contingencies (Details) [Line Items]

Square feet | m²

26,963

Commitments and Contingencies_3

Commitments and Contingencies (Details) - Schedule of Lease Expense - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Operating leases:
Operating lease cost	$ 126	$ 190	$ 316	$ 380
Variable lease cost	(9)	11	49	16
Operating lease expense	$ 117	$ 201	$ 365	$ 396

Commitments and Contingencies_4

Commitments and Contingencies (Details) - Schedule of Supplemental Cash Flow Information Related to Leases - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Schedule of Supplemental Cash Flow Information Related to Leases [Abstract]
Operating cash flows - operating leases	$ 119	$ 189	$ 311	$ 341
Right-of-use assets obtained in exchange for operating lease liabilities				$ 2,336
Weighted-average remaining lease term – operating leases (in years)	1 year 8 months 12 days	3 years 8 months 12 days	1 year 8 months 12 days	3 years 8 months 12 days
Weighted-average discount rate – operating leases	12%	12%	12%	12%

Commitments and Contingencies_5

Commitments and Contingencies (Details) - Schedule of Future Minimum Payments $ in Thousands	Jun. 30, 2023 USD ($)
Schedule of Future Minimum Payments [Abstract]
Six months ended December 31, 2023	$ 392
Year ended December 31, 2024	405
Year ended December 31, 2025	194
Year ended December 31, 2026	100
Year ended December 31, 2027	9
Total	1,100
Less present value discount	(261)
Operating lease liabilities	$ 839

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	1 Months Ended	6 Months Ended
	Jul. 20, 2023	Jun. 30, 2023	Oct. 16, 2023	Aug. 02, 2023	Jul. 14, 2023	Jul. 11, 2023	Jul. 10, 2023	Dec. 31, 2022	Dec. 09, 2021
Subsequent Events (Details) [Line Items]
Security deposit									$ 150,000
Common stock		$ 6,000						$ 2,000
Purchase agreement percentage		97%
Net proceeds		$ 283,949
Commissions and expenses		$ 30,000
Weighted average price per share (in Dollars per share)		$ 1.81
Gross proceeds		$ 3
Combined additional amount		2,100,000
Excess stockholder equity levels amount		$ 2,500,000
ELOC [Member]
Subsequent Events (Details) [Line Items]
Sell placement shares (in Shares)		21,840
ATM Offering [Member]
Subsequent Events (Details) [Line Items]
Common stock		$ 1,590,000
Sell placement shares (in Shares)		5,100,000
Net proceeds		$ 421,758
Weighted average price per share (in Dollars per share)		$ 10.38
Common Stock [Member]
Subsequent Events (Details) [Line Items]
Common stock		$ 500,000
ATM Offering [Member]
Subsequent Events (Details) [Line Items]
Weighted average price per share (in Dollars per share)		$ 3.94
ELOC [Member]
Subsequent Events (Details) [Line Items]
Ownership percentage		4.99%
Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Security deposit							$ 100,000
Security paying							$ 20,000
Investor agreed shares (in Shares)					25,143	152,085
Common stock					$ 132,000	$ 931,000
Shares of common stock (in Shares)				12,374
Aggregate purchase price	$ 50,000,000
Additional shares issued (in Shares)			87,417
Subsequent Event [Member] | Warrant [Member]
Subsequent Events (Details) [Line Items]
Shares of common stock (in Shares)				52,000
Selling, General and Administrative Expenses [Member]
Subsequent Events (Details) [Line Items]
Commissions and expenses		$ 760,000